TAUNTON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urina	<u>ry</u>		<u>M</u>	<u>[elanoma of</u>	<u>Skin</u>				
Male	35.88	36	100	Male	18.88	10	53 #-		
Female	14.72	12	81	Female	16.79	11	66		
Total	50.60	48	95	Total	35.67	21	59 #-		
Brain and Cen	<u>tral Nervous</u>	System	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>				
Male	12.83	7	55	Male	6.47	6	93		
Female	12.88	11	85	Female	6.55	7	107		
Total	25.71	18	70	Total	13.02	13	100		
<u>Breast</u>			Non-Hodgkin's Lymphoma						
Male	1.91	1	NC*	Male	27.42	32	117		
Female	234.21	207	88	Female	26.39	27	102		
Total	236.13	208	88	Total	53.81	59	110		
Cervix Uteri			<u>O</u>	ral Cavity a	nd Pharynx				
				Male	24.49	27	110		
Female	15.43	16	104	Female	11.89	13	109		
				Total	36.38	40	110		
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>					
Male	95.16	62	65 ^-						
Female	98.63	89	90	Female	28.48	32	112		
Total	193.79	151	78 ~-						
Esophagus			<u>Pa</u>	ancreas					
Male	12.21	13	106	Male	13.20	14	106		
Female	4.89	6	123	Female	15.51	11	71		
Total	17.10	19	111	Total	28.71	25	87		
Hodgkin's Dis	<u>ease</u>		<u>P</u> 1	<u>rostate</u>					
Male	6.22	4	NC*	Male	212.00	191	90		
Female	5.30	4	NC*						
Total	11.52	8	69						
Kidney and Re	enal Pelvis		<u>St</u>	<u>omach</u>					
Male	21.08	30	142	Male	15.81	24	152		
Female	13.88	10	72	Female	10.81	8	74		
Total	34.96	40	114	Total	26.62	32	120		
<u>Larynx</u>			<u>T</u>	<u>estis</u>					
Male	13.19	10	76	Male	9.32	9	97		
Female	3.92	3	NC*						
Total	17.11	13	76						
Leukemia			<u>T</u>	<u>hyroid</u>					

1 of 92

Male	14.81	12	81	Male	3.71	4	NC*
Female	12.18	14	115	Female	10.86	9	83
Total	26.98	26	96	Total	14.58	13	89
Liver and Intr	ahepatic Bile	Ducts	<u>U1</u>	NOS			
Male	5.93	8	135				
Female	2.98	2	NC*	Female	43.60	30	69 #-
Total	8.91	10	112				
Lung and Broi	<u>nchus</u>		<u>Al</u>	l Sites / Ty	pes		
Male	117.02	120	103	Male	719.01	680	95
Female	89.78	88	98	Female	733.83	665	91 #-
Total	206.80	208	101	Total	1452.83	1345	93 ~-

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} <= 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

TEMPLETON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		$\mathbf{\underline{Exp}}$	<u>Obs</u>	<u>SIR</u>	
Bladder, Urina	ry		<u>M</u>	<u>lelanoma of S</u>	<u>Skin</u>			
Male	5.80	11	190	Male	2.90	2	NC*	
Female	1.84	4	NC*	Female	2.09	1	NC*	
Total	7.64	15	196 #+	Total	4.98	3	NC*	
Brain and Cen	tral Nervous S	l Nervous System Multiple Myeloma						
Male	1.90	2	NC*	Male	1.04	1	NC*	
Female	1.62	1	NC*	Female	0.82	3	NC*	
Total	3.52	3	NC*	Total	1.86	4	NC*	
Breast			<u>N</u>	on-Hodgkin's	s Lymphoma	<u>a</u>		
Male	0.31	1	NC*	Male	4.16	3	NC*	
Female	29.28	33	113	Female	3.28	6	183	
Total	29.58	34	115	Total	7.44	9	121	
Cervix Uteri			<u>O</u> :	ral Cavity an	d Pharynx			

^{* =} SIR and statistical significance not calculated when Obs < 5

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

				Male	3.83	1	NC*
Female	1.91	2	NC*	Female	1.49	1	NC*
				Total	5.32	2	NC*
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	15.30	10	65				
Female	12.26	9	73	Female	3.56	5	140
Total	27.56	19	69				
Esophagus			<u>Pa</u>	ancreas			
Male	1.95	1	NC*	Male	2.09	1	NC*
Female	0.61	0	NC*	Female	1.93	2	NC*
Total	2.56	1	NC*	Total	4.02	3	NC*
Hodgkin's Dis	ease		<u>P</u> 1	<u>rostate</u>			
Male	0.83	1	NC*	Male	33.56	20	60 #-
Female	0.65	0	NC*				
Total	1.49	1	NC*				
Kidney and Re	enal Pelvis		<u>St</u>	<u>omach</u>			
Male	3.28	3	NC*	Male	2.56	2	NC*
Female	1.74	1	NC*	Female	1.34	1	NC*
Total	5.02	4	NC*	Total	3.90	3	NC*
<u>Larynx</u>			<u>T</u>	estis_			
Male	2.08	3	NC*	Male	1.16	3	NC*
Female	0.50	1	NC*				
Total	2.58	4	NC*				
<u>Leukemia</u>			<u>Tl</u>	<u>nyroid</u>			
Male	2.27	0	NC*	Male	0.52	0	NC*
Female	1.53	0	NC*	Female	1.34	0	NC*
Total	3.79	0	NC*	Total	1.86	0	NC*
Liver and Intr	ahepatic Bile l	<u>Ducts</u>	<u>U</u> 1	teri, Corpus	and Uterus	, NOS	
Male	0.93	0	NC*				
Female	0.37	0	NC*	Female	5.48	7	128
Total	1.30	0	NC*				
Lung and Bron	nchus_		<u>A</u>]	ll Sites / Ty	<u>pes</u>		
Male	18.43	13	71	Male	112.83	82	73 ~-
Female	11.23	11	98	Female	91.61	94	103
Total	29.66	24	81	Total	204.44	176	86 #-

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

3 of 92

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

TEWKSBURY

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	SIR	
<u>Bladder, Urina</u>	<u>ry</u>		$\underline{\mathbf{M}}$	<u>lelanoma of</u>	<u>Skin</u>			
Male	17.78	24	135	Male	10.32	12	116	
Female	6.22	6	96	Female	8.30	12	145	
Total	24.00	30	125	Total	18.62	24	129	
Brain and Cen	tral Nervous	<u>System</u>	$\underline{\mathbf{M}}$	ultiple Mye	<u>eloma</u>			
Male	7.15	8	112	Male	3.26	3	NC*	
Female	6.20	2	NC*	Female	2.81	2	NC*	
Total	13.35	10	75	Total	6.07	5	82	
Breast			Non-Hodgkin's Lymphoma					
Male	0.99	1	NC*	Male	14.72	11	75	
Female	110.92	109	98	Female	11.69	5	43 #-	
Total	111.91	110	98	Total	26.41	16	61 #-	
<u>Cervix Uteri</u>			<u>O</u> :	ral Cavity a	<u>nd Pharynx</u>			
				Male	13.64	17	125	
Female	8.00	3	NC*	Female	5.52	4	NC*	
				Total	19.16	21	110	
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>				
Male	47.33	54	114					
Female	40.78	46	113	Female	13.80	16	116	
Total	88.11	100	113					
Esophagus			<u>Pa</u>	<u>ancreas</u>				
Male	6.50	7	108	Male	6.82	7	103	
Female	2.02	2	NC*	Female	6.48	5	77	
Total	8.52	9	106	Total	13.30	12	90	
Hodgkin's Dis	<u>ease</u>		<u>P</u> 1	<u>rostate</u>				
Male	3.60	4	NC*	Male	104.68	93	89	
Female	2.76	3	NC*					
Total	6.36	7	110					
Kidney and Re	enal Pelvis		<u>St</u>	<u>omach</u>				
Male	11.36	7	62	Male	7.90	8	101	
Female	6.27	12	192	Female	4.49	1	NC*	
Total	17.62	19	108	Total	12.38	9	73	
<u>Larynx</u>			<u>To</u>	<u>estis</u>				

[~] indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	7.19	9	125	Male	5.58	4	NC*
Female	1.88	0	NC*				
Total	9.07	9	99				
Leukemia			<u>Tì</u>	<u>ıyroid</u>			
Male	7.82	7	89	Male	2.17	1	NC*
Female	5.59	5	89	Female	5.70	10	175
Total	13.41	12	89	Total	7.87	11	140
<u>Liver and Intrahepatic Bile Ducts</u> <u>Uteri, Corpus and Uter</u>					and Uterus	NOS	
Male	3.13	4	NC*				
Male Female	3.13 1.29	4 0	NC* NC*	Female	20.54	13	63
				Female	20.54	13	63
Female	1.29 4.42	0	NC* NC*	Female		13	63
Female Total	1.29 4.42	0	NC* NC*			13 378	63
Female Total Lung and Bron	1.29 4.42 nchus	0 4	NC* NC* <u>Al</u>	ll Sites / Ty	<u>pes</u>		
Female Total Lung and Brown Male	1.29 4.42 nchus 61.04	0 4 74	NC* NC* <u>Al</u> 121	ll Sites / Ty Male	<u>pes</u> 369.92	378	102

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

TISBURY

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urinar	<u>y</u>	Melanoma of Skin							
Male	2.66	2	NC*	Male	1.31	4	NC*		
Female	1.16	0	NC*	Female	1.18	2	NC*		
Total	3.82	2	NC*	Total	2.49	6	241		
Brain and Cent	ral Nervous S	<u>System</u>	$\underline{\mathbf{M}}$	<u>lultiple Myel</u>	<u>oma</u>				
Male	0.85	0	NC*	Male	0.48	0	NC*		
Female	0.91	1	NC*	Female	0.51	1	NC*		
Total	1.77	1	NC*	Total	0.99	1	NC*		
Breast			N	on-Hodgkin's	s Lymphoma	a			

<u>Non-Hodgkin's Lymphoma</u>

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	0.14	0	NC*	Male	1.89	3	NC*
Female	17.15	25	146	Female	2.00	2	NC*
Total	17.29	25	145	Total	3.89	5	129
Cervix Uteri			<u>O</u> 1	ral Cavity a	nd Pharynx		
				Male	1.75	3	NC*
Female	1.03	0	NC*	Female	0.89	5	564 ~+
				Total	2.64	8	303 #+
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	7.07	9	127	-			
Female	7.84	4	NC*	Female	2.04	6	294 #+
Total	14.91	13	87				
Esophagus			Pa	ancreas_			
Male	0.90	1	NC*	Male	0.97	1	NC*
Female	0.39	0	NC*	Female	1.22	6	491 ~+
Total	1.29	1	NC*	Total	2.19	7	319 #+
Hodgkin's Dis	ease_		Pr	<u>rostate</u>			
Male	0.36	1	NC*	Male	15.99	19	119
Female	0.34	0	NC*				
Total	0.69	1	NC*				
Kidney and Re	enal Pelvis		St	<u>omach</u>			
Male	1.53	0	NC*	Male	1.16	0	NC*
Female	1.04	3	NC*	Female	0.86	2	NC*
Total	2.57	3	NC*	Total	2.02	2	NC*
<u>Larynx</u>			Te	estis_			
Male	0.97	1	NC*	 Male	0.49	1	NC*
Female	0.29	1	NC*				
Total	1.26	2	NC*				
Leukemia			<u>T</u>	nyroid			
Male	1.02	2	NC*	Male	0.23	0	NC*
Female	0.89	0	NC*	Female	0.71	0	NC*
Total	1.91	2	NC*	Total	0.94	0	NC*
Liver and Intra	ahepatic Bile	Ducts	<u>U1</u>	teri, Corpus	and Uterus.	NOS	
Male	0.43	₁	NC*		_		
Female	0.23	0	NC*	Female	3.22	5	155
Total	0.66	1	NC*				
Lung and Bron	chus_		Al	ll Sites / Ty	pes_		
Male	8.71	11	126	Male	 52.54	61	116
Female	6.79	10	147	Female	54.82	79	144 ~+
Total	15.50	21	135	Total	107.36	140	130 ~+

 $\mathbf{Exp} = \text{expected case count}$, based on the Massachusetts average age-specific incidence rates for this cancer $\mathbf{Obs} = \text{observed case count}$

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} <= 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} <= 0.001$ level, as well as at the $\mathbf{p} <= 0.05$ and $\mathbf{p} <= 0.01$ levels

TOLLAND

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urina	<u>ry</u>		$\underline{\mathbf{M}}$	<u>lelanoma of S</u>	<u>Skin</u>		
Male	0.24	0	NC*	Male	0.13	0	NC*
Female	0.06	0	NC*	Female	0.09	0	NC*
Total	0.31	0	NC*	Total	0.22	0	NC*
Brain and Cent	<u>tral Nervous S</u>	<u>System</u>	$\underline{\mathbf{M}}$	<u>lultiple Myel</u>	<u>oma</u>		
Male	0.09	0	NC*	Male	0.04	0	NC*
Female	0.07	0	NC*	Female	0.03	0	NC*
Total	0.15	0	NC*	Total	0.07	0	NC*
Breast			No	on-Hodgkin's	s Lymphoma	<u>ı</u>	
Male	0.01	0	NC*	Male	0.18	0	NC*
Female	1.19	0	NC*	Female	0.12	0	NC*
Total	1.20	0	NC*	Total	0.31	0	NC*
Cervix Uteri			<u>O</u> :	ral Cavity an	d Pharynx		
				Male	0.19	0	NC*
Female	0.08	0	NC*	Female	0.06	0	NC*
				Total	0.25	0	NC*
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	0.65	0	NC*				
Female	0.42	1	NC*	Female	0.15	0	NC*
Total	1.07	1	NC*				
Esophagus			<u>Pa</u>	<u>ancreas</u>			
Male	0.09	0	NC*	Male	0.09	0	NC*
Female	0.02	0	NC*	Female	0.07	0	NC*
Total	0.11	0	NC*	Total	0.16	0	NC*
Hodgkin's Disc	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Male	0.04	0	NC*	Male	1.46	0	NC*
Female	0.03	1	NC*				
Total	0.06	1	NC*				

Kidney and Re	nal Pelvis	<u>l Pelvis</u> <u>Stomach</u>					
Male	0.15	0	NC*	Male	0.11	0	NC*
Female	0.07	0	NC*	Female	0.04	0	NC*
Total	0.22	0	NC*	Total	0.15	0	NC*
<u>Larynx</u>							
Male	0.10	0	NC*	Male	0.05	0	NC*
Female	0.02	0	NC*				
Total	0.12	0	NC*				
Leukemia			<u>Tl</u>	<u>nyroid</u>			
Male	0.10	0	NC*	Male	0.02	0	NC*
Female	0.06	0	NC*	Female	0.06	0	NC*
Total	0.16	0	NC*	Total	0.08	0	NC*
Liver and Intra	<u>thepatic Bile D</u>	<u>ucts</u>	<u>U</u> 1	teri, Corpus	and Uterus,	NOS_	
Male	0.04	0	NC*				
Female	0.01	0	NC*	Female	0.23	0	NC*
Total	0.06	0	NC*				
Lung and Bron	<u>chus</u>		$\underline{\mathbf{A}}$	ll Sites / Typ	<u>es</u>		
Male	0.85	1	NC*	Male	5.00	1	NC*
Female	0.45	1	NC*	Female	3.57	3	NC*
Total	1.30	2	NC*	Total	8.56	4	NC*

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

TOPSFIELD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary	<u>-</u>		$\underline{\mathbf{M}}$	<u>lelanoma of S</u>	<u>Skin</u>		
Male	5.38	2	NC*	Male	2.68	1	NC*
Female	2.03	2	NC*	Female	2.08	2	NC*
Total	7.41	4	NC*	Total	4.77	3	NC*

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Brain and Cent	ral Nervous	<u>System</u>	em <u>Multiple Myeloma</u>				
Male	1.72	1	NC*	Male	0.97	1	NC*
Female	1.59	3	NC*	Female	0.88	1	NC*
Total	3.31	4	NC*	Total	1.85	2	NC*
Breast			<u>N</u>	on-Hodgkin	's Lymphom	<u>ıa</u>	
Male	0.29	0	NC*	Male	3.78	1	NC*
Female	30.46	37	121	Female	3.45	2	NC*
Total	30.75	37	120	Total	7.23	3	NC*
Cervix Uteri			<u>O</u>	ral Cavity a	nd Pharynx		
				Male	3.66	4	NC*
Female	1.79	0	NC*	Female	1.59	2	NC*
				Total	5.25	6	114
Colon / Rectum	•		<u>O</u>	<u>vary</u>			
Male	14.18	5	35 #-				
Female	13.59	14	103	Female	3.63	3	NC*
Total	27.77	19	68				
Esophagus			<u>Pa</u>	ancreas			
Male	1.86	1	NC*	Male	1.95	0	NC*
Female	0.67	0	NC*	Female	2.09	1	NC*
Total	2.53	1	NC*	Total	4.04	1	NC*
Hodgkin's Dise	ase		<u>P</u> 1	<u>rostate</u>			
Male	0.69	0	NC*	Male	31.05	35	113
Female	0.54	1	NC*				
Total	1.24	1	NC*				
Kidney and Rei	<u>nal Pelvis</u>		<u>St</u>	<u>omach</u>			
Male	3.08	2	NC*	Male	2.37	0	NC*
Female	1.78	1	NC*	Female	1.52	0	NC*
Total	4.87	3	NC*	Total	3.89	0	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	2.00	1	NC*	Male	0.91	0	NC*
Female	0.52	0	NC*				
Total	2.52	1	NC*				
<u>Leukemia</u>				<u>hyroid</u>			
Male	2.06	1	NC*	Male	0.46	1	NC*
Female	1.56	2	NC*	Female	1.21	0	NC*
Total	3.62	3	NC*	Total	1.67	1	NC*
Liver and Intra	-			<u>teri, Corpus</u>	s and Uterus	<u>NOS</u>	
Male	0.87	2	NC*				
Female	0.39	0	NC*	Female	5.71	3	NC*
Total	1.26	2	NC*				
Lung and Brono			_	ll Sites / Ty			
Male	17.32	7	40 ~-	Male	104.51	66	63 ^-
Female	11.42	8	70	Female	95.79	85	89
Total	28.74	15	52 ~-	Total	200.30	151	75 ^-

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

TOWNSEND

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urina	<u>ry</u>		<u>M</u>	elanoma of S	<u>Skin</u>				
Male	3.71	6	162	Male	2.43	2	NC*		
Female	1.31	2	NC*	Female	2.08	2	NC*		
Total	5.02	8	159	Total	4.50	4	NC*		
Brain and Cen	<u>tral Nervous S</u>	<u>System</u>	<u>M</u>	ultiple Myel	<u>oma</u>				
Male	1.82	1	NC*	Male	0.69	1	NC*		
Female	1.58	0	NC*	Female	0.60	1	NC*		
Total	3.40	1	NC*	Total	1.29	2	NC*		
Breast			Non-Hodgkin's Lymphoma						
Male	0.21	0	NC*	Male	3.48	1	NC*		
Female	26.00	26	100	Female	2.67	4	NC*		
Total	26.21	26	99	Total	6.15	5	81		
<u>Cervix Uteri</u>			<u>O</u> :	ral Cavity an	<u>d Pharynx</u>				
				Male	3.12	1	NC*		
Female	2.12	2	NC*	Female	1.26	2	NC*		
				Total	4.38	3	NC*		
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>					
Male	9.82	15	153						
Female	8.53	9	105	Female	3.35	5	149		
Total	18.35	24	131						
Esophagus			<u>Pa</u>	<u>ancreas</u>					
Male	1.41	1	NC*	Male	1.44	4	NC*		
Female	0.42	0	NC*	Female	1.38	1	NC*		
Total	1.82	1	NC*	Total	2.82	5	177		

Hodgkin's Disease			<u>1</u>	Prostate				
Male	1.03	0	NC*	Male	20.49	18	88	
Female	0.82	0	NC*					
Total	1.85	0	NC*					
Kidney and R	<u> Renal Pelvis</u>		5	Stomach_				
Male	2.52	0	NC*	Male	1.69	2	NC*	
Female	1.45	3	NC*	Female	0.93	0	NC*	
Total	3.97	3	NC*	Total	2.62	2	NC*	
<u>Larynx</u>]					
Male	1.57	0	NC*	Male	1.63	2	NC*	
Female	0.43	0	NC*					
Total	1.99	0	NC*					
Leukemia]	<u> Thyroid</u>				
Male	1.92	3	NC*	Male	0.57	0	NC*	
Female	1.41	2	NC*	Female	1.57	4	NC*	
Total	3.32	5	150	Total	2.14	4	NC*	
Liver and Int	rahepatic Bil	le Ducts	<u>I</u>	Uteri, Corpus and Uterus, NOS				
Male	0.69	1	NC*					
Female	0.29	0	NC*	Female	4.72	11	233 #+	
Total	0.98	1	NC*					
Lung and Bronchus			<u> </u>	All Sites / Types				
Male	12.70	8	63	Male	79.16	70	88	
Female	9.06	7	77	Female	77.38	90	116	
Total	21.75	15	69	Total	156.54	160	102	

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

TRURO

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

SIR Exp Obs **SIR** Exp **Obs**

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Bladder, Urinar	<u>y</u>	Melanoma of Skin					
Male	1.94	2	NC*	Male	0.93	1	NC*
Female	0.60	1	NC*	Female	0.64	0	NC*
Total	2.54	3	NC*	Total	1.56	1	NC*
Brain and Cent	<u>ral Nervous S</u>	<u>System</u>	$\underline{\mathbf{M}}$	<u>lultiple Mye</u>	<u>loma</u>		
Male	0.58	1	NC*	Male	0.35	1	NC*
Female	0.48	0	NC*	Female	0.27	0	NC*
Total	1.06	1	NC*	Total	0.62	1	NC*
Breast			<u>N</u>	<u>on-Hodgkin'</u>	s Lymphoma	<u>a</u> _	
Male	0.10	1	NC*	Male	1.32	2	NC*
Female	9.49	10	105	Female	1.05	0	NC*
Total	9.59	11	115	Total	2.36	2	NC*
<u>Cervix Uteri</u>			<u>O</u>	<u>ral Cavity ar</u>	nd Pharynx		
				Male	1.28	2	NC*
Female	0.55	1	NC*	Female	0.48	0	NC*
				Total	1.76	2	NC*
Colon / Rectum				<u>vary</u>			
Male	5.16	5	97				
Female	4.02	2	NC*	Female	1.13	2	NC*
Total	9.17	7	76				
Esophagus			<u>Pa</u>	ancreas			
Male	0.66	1	NC*	Male	0.71	3	NC*
Female	0.20	0	NC*	Female	0.64	1	NC*
Total	0.86	1	NC*	Total	1.35	4	NC*
Hodgkin's Dise	<u>ase</u>		<u>P</u> 1	<u>rostate</u>			
Male	0.22	0	NC*	Male	11.81	11	93
Female	0.16	0	NC*				
Total	0.38	0	NC*				
Kidney and Rer	<u>nal Pelvis</u>		<u>Stomach</u>				
Male	1.10	0	NC*	Male	0.84	3	NC*
Female	0.56	0	NC*	Female	0.44	1	NC*
Total	1.67	0	NC*	Total	1.28	4	NC*
<u>Larynx</u>			\mathbf{T}	<u>estis</u>			
Male	0.72	0	NC*	Male	0.27	2	NC*
Female	0.17	0	NC*				
Total	0.88	0	NC*				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	0.70	3	NC*	Male	0.15	0	NC*
Female	0.45	1	NC*	Female	0.37	0	NC*
Total	1.15	4	NC*	Total	0.52	0	NC*
Liver and Intra	<u>hepatic Bile I</u>	<u>Ducts</u>		<u>teri, Corpus</u>	and Uterus,	NOS	
Male	0.31	0	NC*				
Female	0.12	2	NC*	Female	1.82	1	NC*
Total	0.43	2	NC*				

12 of 92

Lung and Bro		All Sites / Types					
Male	6.40	4	NC*	Male	38.09	47	123
Female	3.74	2	NC*	Female	29.51	26	88
Total	10.14	6	59	Total	67.59	73	108

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

TYNGSBOROUGH

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary	•		$\underline{\mathbf{N}}$	<u> Ielanoma of</u>	<u>Skin</u>		
Male	4.13	5	121	Male	2.68	3	NC*
Female	1.53	2	NC*	Female	2.35	4	NC*
Total	5.65	7	124	Total	5.03	7	139
Brain and Centra	al Nervou	<u>is System</u>	$\underline{\mathbf{N}}$	<u> Iultiple Mye</u>	<u>eloma</u>		
Male	1.98	1	NC*	Male	0.77	1	NC*
Female	1.77	2	NC*	Female	0.70	1	NC*
Total	3.74	3	NC*	Total	1.47	2	NC*
Breast		Non-Hodgkin's Lymphoma					
Male	0.24	0	NC*	Male	3.82	5	131
Female	29.86	28	94	Female	3.06	5	164
Total	30.10	28	93	Total	6.88	10	145
<u>Cervix Uteri</u>			<u>O</u>	oral Cavity a	<u>nd Pharynx</u>		
				Male	3.50	5	143
Female	2.38	1	NC*	Female	1.45	0	NC*
				Total	4.96	5	101
Colon / Rectum	<u>Ovary</u>						
Male	11.00	11	100				
Female	9.89	11	111	Female	3.81	9	236 #+
Total	20.89	22	105				

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female 0.49 1 NC* Female 1.60 1 NC Total 2.08 3 NC* Total 3.24 2 NC Hodgkin's Disease Prostate Male 1.09 2 NC* Male 23.93 15 6 Female 0.88 2 NC* Total 1.97 4 NC*	C* C* C*
Total 2.08 3 NC* Total 3.24 2 NC Hodgkin's Disease Prostate Male 1.09 2 NC* Male 23.93 15 6 Female 0.88 2 NC* Total 1.97 4 NC*	C*
Hodgkin's Disease Prostate Male 1.09 2 NC* Male 23.93 15 6 Female 0.88 2 NC* Total 1.97 4 NC*	
Male 1.09 2 NC* Male 23.93 15 6 Female 0.88 2 NC* Total 1.97 4 NC*	53
Female 0.88 2 NC* Total 1.97 4 NC*	63
Total 1.97 4 NC*	
Kidney and Renal Pelvis Stomach	
Male 2.85 6 210 Male 1.86 2 NO	C*
Female 1.66 1 NC* Female 1.08 2 NC	C*
Total 4.52 7 155 Total 2.94 4 NO	C*
<u>Larynx</u> <u>Testis</u>	
Male 1.79 2 NC* Male 1.72 2 NC	C*
Female 0.50 0 NC*	
Total 2.29 2 NC*	
<u>Leukemia</u> <u>Thyroid</u>	
Male 2.07 2 NC* Male 0.62 0 NC	C*
Female 1.55 2 NC* Female 1.74 2 NC	C*
Total 3.63 4 NC* Total 2.36 2 NC	C*
<u>Liver and Intrahepatic Bile Ducts</u> <u>Uteri, Corpus and Uterus, NOS</u>	
Male 0.78 1 NC*	
Female 0.33 0 NC* Female 5.46 7 12	28
Total 1.11 1 NC*	
<u>Lung and Bronchus</u> <u>All Sites / Types</u>	
Male 14.67 15 102 Male 89.58 89 9	99
Female 10.50 13 124 Female 88.75 101 11	14
Total 25.17 28 111 Total 178.33 190 10	07

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

TYRINGHAM

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Cancer Incidence by Sex, 1990 - 1995 Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				<u>lelanoma of S</u>			
Male	0.38	0	NC*	Male	0.19	0	NC*
Female	0.11	0	NC*	Female	0.12	0	NC*
Total	0.49	0	NC*	Total	0.31	0	NC*
Brain and Centr				<u>lultiple Myel</u>			
Male	0.12	0	NC*	Male	0.07	0	NC*
Female	0.10	0	NC*	Female	0.05	0	NC*
Total	0.22	0	NC*	Total	0.12	0	NC*
<u>Breast</u>			· · · · · · · · · · · · · · · · · · ·	<u>on-Hodgkin's</u>			
Male	0.02	0	NC*	Male	0.27	0	NC*
Female	1.86	2	NC*	Female	0.19	0	NC*
Total	1.88	2	NC*	Total	0.46	0	NC*
<u>Cervix Uteri</u>			<u>O</u>	<u>ral Cavity an</u>	<u>d Pharynx</u>		
				Male	0.26	1	NC*
Female	0.11	0	NC*	Female	0.09	0	NC*
				Total	0.35	1	NC*
Colon / Rectum			<u>O</u>	<u>vary</u>			
Male	1.00	1	NC*				
Female	0.71	0	NC*	Female	0.22	0	NC*
Total	1.71	1	NC*				
Esophagus			<u>Pa</u>	ancreas			
Male	0.13	0	NC*	Male	0.14	0	NC*
Female	0.04	0	NC*	Female	0.12	0	NC*
Total	0.17	0	NC*	Total	0.26	0	NC*
Hodgkin's Dise	ase_		<u>P</u> 1	<u>rostate</u>			
Male	0.05	0	NC*	Male	2.25	1	NC*
Female	0.03	1	NC*				
Total	0.08	1	NC*				
Kidney and Ren	al Pelvis		<u>St</u>	<u>omach</u>			
Male	0.22	0	NC*	Male	0.16	0	NC*
Female	0.11	0	NC*	Female	0.08	0	NC*
Total	0.33	0	NC*	Total	0.24	0	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.14	1	NC*	Male	0.06	0	NC*
Female	0.03	0	NC*				
Total	0.18	1	NC*				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	0.15	0	NC*	Male	0.03	0	NC*
Female	0.09	0	NC*	Female	0.07	0	NC*

15 of 92

Total	0.23	0	NC*	Total	0.11	0	NC*	
Liver and Intrahepatic Bile Ducts			<u>Uteri, Corpus and Uterus, NOS</u>					
Male	0.06	0	NC*					
Female	0.02	0	NC*	Female	0.36	0	NC*	
Total	0.08	0	NC*					
Lung and Brond	<u>chus</u>		All Sites / Types					
Male	1.26	1	NC*	Male	7.48	6	80	
Female	0.74	0	NC*	Female	5.65	3	NC*	
Total	2.01	1	NC*	Total	13.13	9	69	

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

UPTON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	<u>SIR</u>			
Bladder, Urina	ry		<u>M</u>	elanoma of	<u>Skin</u>					
Male	3.44	5	145	Male	1.91	0	NC*			
Female	1.19	2	NC*	Female	1.49	2	NC*			
Total	4.63	7	151	Total	3.41	2	NC*			
Brain and Cen	tral Nervous S	<u>System</u>	<u>M</u>	ultiple Mye	<u>loma</u>					
Male	1.29	2	NC*	Male	0.63	0	NC*			
Female	1.14	5	439 #+	Female	0.54	0	NC*			
Total	2.43	7	288 #+	Total	1.17	0	NC*			
Breast			<u>N</u>	on-Hodgkin	's Lymphoma	<u>1</u>				
Male	0.19	0	NC*	Male	2.71	3	NC*			
Female	20.52	21	102	Female	2.20	2	NC*			
Total	20.71	21	101	Total	4.91	5	102			
Cervix Uteri		Oral Cavity and Pharynx								
				Male	2.57	3	NC*			
Female	1.41	2	NC*	Female	1.03	3	NC*			

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

				Total	3.60	6	167
Colon / Rectur	<u>n</u> _		<u>(</u>	<u>Ovary</u>			
Male	9.13	10	109				
Female	7.84	13	166	Female	2.53	1	NC*
Total	16.97	23	136				
Esophagus			<u>I</u>	Pancreas Pancreas			
Male	1.25	0	NC*	Male	1.30	1	NC*
Female	0.39	1	NC*	Female	1.26	0	NC*
Total	1.64	1	NC*	Total	2.56	1	NC*
Hodgkin's Dis	sease_		<u>I</u>	<u>Prostate</u>			
Male	0.60	1	NC*	Male	20.03	20	100
Female	0.48	1	NC*				
Total	1.08	2	NC*				
Kidney and R	<u>enal Pelvis</u>		<u>S</u>	Stomach_			
Male	2.15	2	NC*	Male	1.52	0	NC*
Female	1.19	0	NC*	Female	0.85	2	NC*
Total	3.34	2	NC*	Total	2.37	2	NC*
<u>Larynx</u>			7	<u> Testis</u>			
Male	1.37	1	NC*	Male	0.90	1	NC*
Female	0.35	0	NC*				
Total	1.72	1	NC*				
<u>Leukemia</u>			1	<u>Chyroid</u>			
Male	1.44	2	NC*	Male	0.38	1	NC*
Female	1.03	0	NC*	Female	0.99	3	NC*
Total	2.47	2	NC*	Total	1.37	4	NC*
Liver and Intr	rahepatic Bile	e Ducts	Ī	I <mark>teri, Corpu</mark>	s and Uteru	s, NOS	
Male	0.59	1	NC*				
Female	0.25	0	NC*	Female	3.86	2	NC*
Total	0.84	1	NC*				
Lung and Bro	<u>nchus</u>		<u>A</u>	All Sites / Ty	pes		
Male	11.66	14	120	Male	70.09	72	103
Female	7.78	6	77	Female	62.79	74	118
Total	19.44	20	103	Total	132.88	146	110

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

UXBRIDGE

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urina	<u>ry</u>		<u>M</u>	<u>lelanoma of</u>	<u>Skin</u>		
Male	7.32	11	150	Male	4.01	4	NC*
Female	2.80	6	214	Female	3.40	1	NC*
Total	10.12	17	168	Total	7.41	5	68
Brain and Cent	tral Nervous S	<u>System</u>	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>		
Male	2.75	6	218	Male	1.33	1	NC*
Female	2.61	2	NC*	Female	1.26	1	NC*
Total	5.36	8	149	Total	2.59	2	NC*
Breast			No	<u>on-Hodgkin'</u>	s Lymphoma	<u>ı</u>	
Male	0.40	2	NC*	Male	5.79	4	NC*
Female	46.49	58	125	Female	5.14	5	97
Total	46.88	60	128	Total	10.92	9	82
<u>Cervix Uteri</u>			<u>O</u> :	<u>ral Cavity aı</u>	<u>nd Pharynx</u>		
				Male	5.20	8	154
Female	3.19	4	NC*	Female	2.34	1	NC*
				Total	7.54	9	119
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>			
Male	19.40	13	67				
Female	18.62	14	75	Female	5.72	4	NC*
Total	38.02	27	71				
Esophagus				<u>ancreas</u>			
Male	2.54	1	NC*	Male	2.71	3	NC*
Female	0.92	0	NC*	Female	2.95	6	203
Total	3.47	1	NC*	Total	5.66	9	159
Hodgkin's Disc	<u>ease</u>			<u>rostate</u>			
Male	1.37	0	NC*	Male	42.33	37	87
Female	1.13	1	NC*				
Total	2.50	1	NC*				
Kidney and Re	nal Pelvis			<u>omach</u>			
Male	4.40	4	NC*	Male	3.25	2	NC*
Female	2.74	4	NC*	Female	2.03	3	NC*
Total	7.14	8	112	Total	5.28	5	95
<u>Larynx</u>				<u>estis</u>			
Male	2.75	1	NC*	Male	2.09	1	NC*

Female	0.78	3	NC*				
Total	3.53	4	NC*				
Leukemia			<u>Tl</u>	<u>hyroid</u>			
Male	3.11	2	NC*	Male	0.81	1	NC*
Female	2.43	1	NC*	Female	2.27	2	NC*
Total	5.54	3	NC*	Total	3.09	3	NC*
Liver and Intrahepatic Bile Ducts			<u>Uteri, Corpus and Uterus, NOS</u>				
Male	1.23	2	NC*				
Female	0.58	0	NC*	Female	8.65	7	81
Total	1.81	2	NC*				
Lung and Bron	<u>ichus</u>		All Sites / Types				
Male	23.98	17	71	Male	147.54	123	83 #-
Female	17.63	18	102	Female	144.17	148	103
Total	41.61	35	84	Total	291.71	271	93

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

WAKEFIELD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary			<u>M</u>	elanoma of	<u>Skin</u>		
Male	19.40	17	88	Male	9.85	14	142
Female	8.15	4	NC*	Female	8.76	8	91
Total	27.55	21	76	Total	18.60	22	118
Brain and Central Nervous System			Multiple Myeloma				
Male	6.50	9	138	Male	3.50	4	NC*
Female	6.74	5	74	Female	3.62	2	NC*
Total	13.24	14	106	Total	7.12	6	84
Breast			No	on-Hodgkin'	s Lymphoma	<u>a</u>	
Male	1.03	1	NC*	Male	14.24	10	70

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	125.58	146	116	Female	14.33	16	112
Total	126.61	147	116	Total	28.56	26	91
Cervix Uteri			<u>O</u> 1	ral Cavity a	nd Pharynx		
				Male	12.95	15	116
Female	7.82	5	64	Female	6.42	9	140
				Total	19.37	24	124
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	51.51	48	93				
Female	54.85	60	109	Female	15.08	27	179 ~+
Total	106.36	108	102				
Esophagus			<u>Pa</u>	ncreas			
Male	6.58	3	NC*	Male	7.10	7	99
Female	2.72	3	NC*	Female	8.61	17	198 #+
Total	9.30	6	65	Total	15.71	24	153
Hodgkin's Dis	<u>ease</u>		<u>Pr</u>	<u>costate</u>			
Male	2.94	3	NC*	Male	115.65	132	114
Female	2.58	1	NC*				
Total	5.52	4	NC*				
Kidney and Re	enal Pelvis		<u>St</u>	<u>omach</u>			
Male	11.24	11	98	Male	8.50	14	165
Female	7.52	8	106	Female	6.00	2	NC*
Total	18.76	19	101	Total	14.50	16	110
<u>Larynx</u>			<u>Te</u>	<u>estis</u>			
Male	7.07	7	99	Male	4.26	3	NC*
Female	2.12	5	236				
Total	9.19	12	131				
Leukemia			<u>Tł</u>	<u>nyroid</u>			
Male	7.63	12	157	Male	1.84	1	NC*
Female	6.44	3	NC*	Female	5.42	5	92
Total	14.07	15	107	Total	7.26	6	83
Liver and Intra	<u>ahepatic Bile</u>	<u>Ducts</u>	<u>U1</u>	t <mark>eri, Corpus</mark>	s and Uterus	, NOS	
Male	3.17	2	NC*				
Female	1.63	2	NC*	Female	23.56	19	81
Total	4.80	4	NC*				
Lung and Bron	<u>ichus</u>		<u>A</u> l	ll Sites / Ty	pes		
Male	63.38	58	92	Male	385.27	397	103
Female	49.09	50	102	Female	396.49	425	107
Total	112.47	108	96	Total	781.76	822	105

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

WALES Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
<u>v</u>		<u>M</u>	elanoma of S	<u>Skin</u>		
0.73	2	NC*	Male	0.47	0	NC*
0.24	0	NC*	Female	0.38	0	NC*
0.97	2	NC*	Total	0.86	0	NC*
ral Nervous S	<u>System</u>	<u>M</u>	<u>ultiple Myel</u>	<u>oma</u>		
0.35	0	NC*	Male	0.14	0	NC*
0.29	0	NC*	Female	0.11	0	NC*
0.63	0	NC*	Total	0.25	0	NC*
		<u>N</u>	on-Hodgkin's	s Lymphoma	<u>1</u>	
0.04	0	NC*	Male	0.68	0	NC*
4.72	5	106	Female	0.49	0	NC*
4.77	5	105	Total	1.17	0	NC*
		<u>O</u> :	-	<u>d Pharynx</u>		
			Male	0.62	0	NC*
0.39	0	NC*	Female	0.23	0	NC*
			Total	0.84	0	NC*
			<u>vary</u>			
1.94	2	NC*				
1.59			Female	0.61	0	NC*
3.53	2	NC*				
0.28	0	NC*	Male	0.29	2	NC*
0.08	0	NC*	Female	0.25	1	NC*
0.36	0	NC*	Total	0.54	3	NC*
<u>ase</u>			<u>rostate</u>			
0.19	0	NC*	Male	4.10	1	NC*
0.15	0	NC*				
0.34	0	NC*				
<u>nal Pelvis</u>						
0.50	0	NC*	Male	0.33	0	NC*
	0.73 0.24 0.97 **al Nervous S 0.35 0.29 0.63 0.04 4.72 4.77 0.39 1.94 1.59 3.53 0.28 0.08 0.36 ase 0.19 0.15 0.34 **nal Pelvis	0.73	Mathematical Policy Mathematical Policy	Melanoma of S NC* Male NC* Female NC* Female NC* Total	NC Melanoma of Skin	Melanoma of Skin

Female	0.26	0	NC*	Female	0.18	0	NC*
Total	0.76	0	NC*	Total	0.51	0	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.31	0	NC*	Male	0.30	0	NC*
Female	0.08	0	NC*				
Total	0.39	0	NC*				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	0.36	1	NC*	Male	0.11	0	NC*
Female	0.26	0	NC*	Female	0.29	0	NC*
Total	0.62	1	NC*	Total	0.40	0	NC*
Liver and Intra	<u>hepatic Bile D</u>	<u>ucts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	0.14	0	NC*				
Female	0.05	0	NC*	Female	0.84	0	NC*
Total	0.19	0	NC*				
Lung and Brono	<u>chus</u>		<u>A</u>]	ll Sites / Typ	<u>oes</u>		
Male	2.56	5	195	Male	15.65	13	83
Female	1.61	2	NC*	Female	14.10	8	57
Total	4.17	7	168	Total	29.75	21	71

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

WALPOLE

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urina	<u>ry</u>						
Male	14.45	14	97	Male	8.11	15	185 #+
Female	4.86	8	165	Female	6.19	13	210 #+
Total	19.31	22	114	Total	14.30	28	196 ~+
Brain and Cent	$\underline{\mathbf{M}}$	<u> Iultiple Mye</u>					
Male	5.55	6	108	Male	2.64	0	NC*

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	4.79	5	104	Female	2.24	0	NC*
Total	10.34	11	106	Total	4.89	0	NC*
Breast			<u>N</u>	on-Hodgkin	's Lymphom	<u>a</u>	
Male	0.79	2	NC*	Male	11.58	14	121
Female	86.91	107	123 #+	Female	9.07	9	99
Total	87.70	109	124 #+	Total	20.65	23	111
Cervix Uteri			<u>O</u>	ral Cavity a	nd Pharynx		
				Male	10.81	12	111
Female	5.79	7	121	Female	4.34	7	161
				Total	15.15	19	125
Colon / Rectum	<u>_</u>		<u>O</u>	<u>vary</u>			
Male	38.55	31	80				
Female	31.71	23	73	Female	10.68	14	131
Total	70.25	54	77				
Esophagus			<u>Pa</u>	ancreas			
Male	5.24	7	134	Male	5.54	6	108
Female	1.59	2	NC*	Female	5.17	7	135
Total	6.83	9	132	Total	10.72	13	121
Hodgkin's Disc				<u>rostate</u>			
Male	2.68	4	NC*	Male	87.21	134	154 ^+
Female	1.92	3	NC*				
Total	4.60	7	152				
Kidney and Re				<u>omach</u>			
Male	9.11	8	88	Male	6.37	5	79
Female	5.06	11	217 #+	Female	3.39	2	NC*
Total	14.17	19	134	Total	9.76	7	72
<u>Larynx</u>			·	<u>estis</u>			
Male	5.79	6	104	Male	4.08	4	NC*
Female	1.54	0	NC*				
Total	7.34	6	82				
<u>Leukemia</u>	. 1.	-		<u>hyroid</u>	1 65		Mark
Male	6.16	5	81	Male	1.65	1	NC*
Female	4.22	5	118	Female	4.05	3	NC*
Total	10.38	10 D	96	Total	5.69	4	NC*
Liver and Intra				teri, Corpus	s and Uterus,	<u>NUS</u>	
Male	2.52	0	NC*	F1-	16.60	17	102
Female	1.02	1	NC* NC*	Female	16.60	17	102
Total	3.55	1		II Citog / Tw	mog		
Lung and Bron Male	<u>cnus</u> 49.90	38	76	<u>ll Sites / Ty</u> Male	<u>pes</u> 300.08	329	110
		38 21	63 #-			329 281	
Female Total	33.41 83.31	59	63 #- 71 ~-	Female Total	262.85 562.93	610	107 108
1 Otal	03.31	39	/1 ~-	างเลา	304.33	010	100

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

WALTHAM

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		$\mathbf{\underline{Exp}}$	<u>Obs</u>	<u>SIR</u>	
Bladder, Urina	<u>ry</u>		<u>M</u>	elanoma of	<u>Skin</u>			
Male	40.00	36	90	Male	22.18	21	95	
Female	16.63	23	138	Female	19.36	14	72	
Total	56.63	59	104	Total	41.54	35	84	
Brain and Cen	d Central Nervous System Multiple Myelo			<u>loma</u>				
Male	14.97	14	93	Male	7.23	11	152	
Female	14.44	10	69	Female	7.34	5	68	
Total	29.41	24	82	Total	14.57	16	110	
Breast			No	on-Hodgkin'	s Lymphoma	_		
Male	2.16	2	NC*	Male	32.24	37	115	
Female	263.47	266	101	Female	29.92	36	120	
Total	265.63	268	101	Total	62.16	73	117	
Cervix Uteri			Oral Cavity and Pharynx					
				Male	28.16	29	103	
Female	18.20	21	115	Female	13.34	11	82	
				Total	41.49	40	96	
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>				
Male	106.25	112	105					
Female	111.71	137	123 #+	Female	32.17	29	90	
Total	217.95	249	114 #+					
Esophagus			<u>Pa</u>	<u>ancreas</u>				
Male	13.72	15	109	Male	14.89	13	87	
Female	5.51	3	NC*	Female	17.41	11	63	
Total	19.23	18	94	Total	32.30	24	74	
Hodgkin's Dis	<u>ease</u>		<u>P1</u>	<u>rostate</u>				

Male	7.88	3	NC*	Male	235.89	268	114 #+
Female	6.32	4	NC*				
Total	14.19	7	49				
Kidney and Re	enal Pelvis		St	<u>omach</u>			
Male	23.96	38	159 ~+	Male	17.72	16	90
Female	15.41	21	136	Female	12.35	14	113
Total	39.36	59	150 ~+	Total	30.07	30	100
<u>Larynx</u>			<u>Te</u>	<u>estis</u>			
Male	14.90	11	74	Male	12.79	14	109
Female	4.30	6	140				
Total	19.20	17	89				
Leukemia			<u>Tł</u>	<u> </u>			
Male	16.69	22	132	Male	4.67	5	107
Female	13.69	12	88	Female	12.91	10	77
Total	30.38	34	112	Total	17.57	15	85
Liver and Intra	ahepatic Bile	Ducts	<u>U1</u>	teri, Corpus	s and Uterus.	NOS	
Male	6.72	5	74				
Female	3.33	4	NC*	Female	48.30	39	81
Total	10.05	9	90				
Lung and Bron	<u>ichus</u>		<u>A</u> l	ll Sites / Ty	pes		
Male	131.50	145	110	Male	813.63	864	106
Female	98.86	113	114	Female	826.26	838	101
Total	230.36	258	112	Total	1639.89	1702	104

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

WARE

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary			Melanon	<u>na of Skin</u>		

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	7.80	8	103	Male	3.98	3	NC*
Female	2.92	5	171	Female	3.22	2	NC*
Total	10.72	13	121	Total	7.19	5	70
Brain and Cent		System_	<u>M</u>	ultiple Mye			
Male	2.65	2	NC*	Male	1.41	0	NC*
Female	2.52	1	NC*	Female	1.31	1	NC*
Total	5.17	3	NC*	Total	2.71	1	NC*
Breast			<u>N</u>	on-Hodgkin'	s Lymphoma	<u>L</u>	
Male	0.41	0	NC*	Male	5.77	4	NC*
Female	45.81	38	83	Female	5.20	5	96
Total	46.22	38	82	Total	10.97	9	82
Cervix Uteri			<u>O</u> :	ral Cavity aı	nd Pharynx		
				Male	5.19	5	96
Female	2.90	4	NC*	Female	2.33	2	NC*
				Total	7.52	7	93
Colon / Rectum	_		<u>O</u>	<u>vary</u>			
Male	20.70	19	92				
Female	19.57	24	123	Female	5.54	4	NC*
Total	40.27	43	107				
Esophagus			<u>Pa</u>	ncreas			
Male	2.63	2	NC*	Male	2.84	3	NC*
Female	0.97	2	NC*	Female	3.10	1	NC*
Total	3.60	4	NC*	Total	5.94	4	NC*
Hodgkin's Dise	<u>ease</u>		<u>P1</u>	<u>rostate</u>			
Male	1.23	1	NC*	Male	46.09	44	95
Female	1.00	1	NC*				
Total	2.22	2	NC*				
Kidney and Re	<u>nal Pelvis</u>		St	<u>omach</u>			
Male	4.51	2	NC*	Male	3.43	5	146
Female	2.77	4	NC*	Female	2.12	3	NC*
Total	7.28	6	82	Total	5.55	8	144
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	2.82	1	NC*	Male	1.79	1	NC*
Female	0.78	1	NC*				
Total	3.59	2	NC*				
<u>Leukemia</u>				<u> </u>			
Male	3.11	5	161	Male	0.75	0	NC*
Female	2.39	1	NC*	Female	2.03	1	NC*
Total	5.50	6	109	Total	2.79	1	NC*
Liver and Intra				<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	1.27	0	NC*	_			
Female	0.59	0	NC*	Female	8.62	10	116
Total	1.87	0	NC*				
Lung and Bronchus			<u>A</u>]	ll Sites / Typ	<u>oes</u>		

Male	25.28	28	111	Male	154.60	143	92
Female	18.08	18	100	Female	144.42	146	101
Total	43.36	46	106	Total	299.02	289	97

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

WAREHAM

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urina	ry		$\underline{\mathbf{M}}$	<u>[elanoma of</u>	<u>Skin</u>		
Male	16.42	20	122	Male	8.07	10	124
Female	5.83	13	223 #+	Female	6.49	4	NC*
Total	22.26	33	148 #+	Total	14.56	14	96
Brain and Cen	tral Nervous S	<u>System</u>	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>		
Male	5.36	9	168	Male	2.94	3	NC*
Female	5.05	3	NC*	Female	2.61	4	NC*
Total	10.41	12	115	Total	5.55	7	126
Breast			<u>N</u>	on-Hodgkin	s Lymphom:	<u>a</u>	
Male	0.86	0	NC*	Male	11.75	8	68
Female	92.29	114	124 #+	Female	10.39	8	77
Total	93.15	114	122 #+	Total	22.13	16	72
Cervix Uteri			<u>O</u>	ral Cavity a	nd Pharynx		
				Male	10.57	20	189 #+
Female	5.87	6	102	Female	4.71	7	149
				Total	15.28	27	177 ~+
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	43.54	55	126				
Female	39.01	36	92	Female	11.16	13	116
Total	82.54	91	110				
Esophagus			<u>Pa</u>	ancreas			

27 of 92

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} <= 0.001$ level, as well as at the $\mathbf{p} <= 0.05$ and $\mathbf{p} <= 0.01$ levels

Male	5.45	8	147	Male	5.94	5	84	
Female	1.94	2	NC*	Female	6.16	6	97	
Total	7.39	10	135	Total	12.10	11	91	
Hodgkin's Dis	sease_		<u>Pr</u>	<u>ostate</u>				
Male	2.38	2	NC*	Male	98.09	86	88	
Female	1.98	2	NC*					
Total	4.36	4	NC*					
Kidney and R	Renal Pelvis Stomach							
Male	9.27	11	119	Male	7.19	6	83	
Female	5.52	3	NC*	Female	4.25	5	118	
Total	14.80	14	95	Total	11.44	11	96	
<u>Larynx</u>			<u>Te</u>	<u>estis</u>				
Male	5.82	6	103	Male	3.34	4	NC*	
Female	1.57	4	NC*					
Total	7.40	10	135					
Leukemia			<u>Tì</u>	<u>iyroid</u>				
Male	6.43	3	NC*	Male	1.46	1	NC*	
Female	4.76	2	NC*	Female	4.10	3	NC*	
Total	11.19	5	45	Total	5.56	4	NC*	
Liver and Intr	ahepatic Bile	<u>Ducts</u>	<u>U1</u>	t <mark>eri, Corpus</mark>	and Uterus	s, NOS		
Male	2.64	2	NC*					
Female	1.18	2	NC*	Female	17.36	19	109	
Total	3.82	4	NC*					
Lung and Bro	nchus_		<u>A</u>]	ll Sites / Ty	<u>pes</u>			
Male	52.78	86	163 ^+	Male	322.78	364	113 #+	
Female	35.99	39	108	Female	289.56	318	110	
Total	88.78	125	141 ^+	Total	612.34	682	111 ~+	

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

WARREN

Cancer Incidence by Sex, 1990 - 1995

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urina	<u>ry</u>		$\underline{\mathbf{M}}$	<u>lelanoma of</u>	<u>Skin</u>		
Male	3.21	5	156	Male	1.73	1	NC*
Female	1.16	2	NC*	Female	1.41	4	NC*
Total	4.38	7	160	Total	3.15	5	159
Brain and Cent	tral Nervous S	<u>System</u>	$\underline{\mathbf{M}}$	<u>Iultiple Mye</u>	<u>loma</u>		
Male	1.20	1	NC*	Male	0.59	1	NC*
Female	1.10	1	NC*	Female	0.53	0	NC*
Total	2.30	2	NC*	Total	1.12	1	NC*
Breast			<u>N</u>	on-Hodgkin'	s Lymphoma	<u>1</u>	
Male	0.17	0	NC*	Male	2.50	2	NC*
Female	19.78	14	71	Female	2.13	2	NC*
Total	19.95	14	70	Total	4.63	4	NC*
Cervix Uteri			<u>O</u>	ral Cavity ar	nd Pharynx		
				Male	2.31	1	NC*
Female	1.30	1	NC*	Female	0.99	1	NC*
				Total	3.30	2	NC*
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>			
Male	8.58	14	163				
Female	7.68	7	91	Female	2.43	1	NC*
Total	16.26	21	129				
Esophagus			<u>Pa</u>	ancreas_			
Male	1.14	0	NC*	Male	1.22	0	NC*
Female	0.38	0	NC*	Female	1.23	2	NC*
Total	1.52	0	NC*	Total	2.44	2	NC*
Hodgkin's Disc	ease_		<u>P</u> 1	<u>rostate</u>			
Male	0.56	0	NC*	Male	19.51	15	77
Female	0.44	1	NC*				
Total	1.01	1	NC*				
Kidney and Re	enal Pelvis		St	tomach_			
Male	1.99	3	NC*	Male	1.41	2	NC*
Female	1.16	2	NC*	Female	0.83	0	NC*
Total	3.15	5	159	Total	2.24	2	NC*
<u>Larynx</u>			$\underline{\mathbf{T}}$	<u>estis</u>			
Male	1.25	3	NC*	Male	0.81	0	NC*
Female	0.34	0	NC*				
Total	1.59	3	NC*				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	1.36	1	NC*	Male	0.34	0	NC*
Female	1.01	0	NC*	Female	0.92	0	NC*
Total	2.38	1	NC*	Total	1.26	0	NC*

Liver and Intrahepatic Bile Ducts			<u>Uteri, Corpus and Uterus, NOS</u>				
Male	0.55	0	NC*				
Female	0.24	0	NC*	Female	3.73	6	161
Total	0.79	0	NC*				
Lung and Bronchus			All Sites / Types				
Male	10.99	15	136	Male	66.11	66	100
Female	7.53	9	120	Female	60.69	55	91
Total	18.52	24	130	Total	126.81	121	95

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

WARWICK

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinar	<u>y</u>		<u>M</u>				
Male	0.56	1	NC*	Male	0.31	1	NC*
Female	0.16	0	NC*	Female	0.20	0	NC*
Total	0.73	1	NC*	Total	0.51	1	NC*
Brain and Cent	ral Nervous S	<u>System</u>	<u>M</u>	ultiple Myel	<u>oma</u>		
Male	0.21	0	NC*	Male	0.10	0	NC*
Female	0.15	0	NC*	Female	0.07	0	NC*
Total	0.36	0	NC*	Total	0.17	0	NC*
Breast			No	on-Hodgkin's	s Lymphom	<u>a</u> _	
Male	0.03	0	NC*	Male	0.45	0	NC*
Female	2.73	2	NC*	Female	0.30	1	NC*
Total	2.76	2	NC*	Total	0.75	1	NC*
Cervix Uteri			<u>O</u> 1	ral Cavity an	d Pharynx		
				Male	0.39	2	NC*
Female	0.18	1	NC*	Female	0.14	0	NC*
				Total	0.53	2	NC*

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Colon / Rectur	<u>n</u>		<u>O</u>	<u>vary</u>			
Male	1.48	1	NC*				
Female	1.08	1	NC*	Female	0.33	0	NC*
Total	2.56	2	NC*				
Esophagus			<u>Pa</u>	ncreas			
Male	0.19	0	NC*	Male	0.20	0	NC*
Female	0.05	0	NC*	Female	0.17	0	NC*
Total	0.24	0	NC*	Total	0.37	0	NC*
Hodgkin's Dis	sease_		<u>Pr</u>	<u>ostate</u>			
Male	0.11	0	NC*	Male	3.11	3	NC*
Female	0.06	0	NC*				
Total	0.17	0	NC*				
Kidney and R	enal Pelvis			<u>omach</u>			
Male	0.33	0	NC*	Male	0.25	0	NC*
Female	0.16	0	NC*	Female	0.12	0	NC*
Total	0.49	0	NC*	Total	0.37	0	NC*
<u>Larynx</u>				<u>estis</u>			
Male	0.20	1	NC*	Male	0.18	0	NC*
Female	0.05	0	NC*				
Total	0.25	1	NC*				
<u>Leukemia</u>			<u>Tł</u>	<u>iyroid</u>			
Male	0.24	0	NC*	Male	0.07	0	NC*
Female	0.14	1	NC*	Female	0.13	0	NC*
Total	0.38	1	NC*	Total	0.19	0	NC*
	<u>ahepatic Bile D</u>	<u>ucts</u>		<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	0.09	0	NC*				
Female	0.03	0	NC*	Female	0.51	0	NC*
Total	0.13	0	NC*				
Lung and Bro				l Sites / Typ			
Male	1.76	3	NC*	Male	11.12	13	117
Female	1.03	1	NC*	Female	8.40	8	95
Total	2.79	4	NC*	Total	19.52	21	108

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

WASHINGTON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				lelanoma of S			
Male	0.60	0	NC*	Male	0.28	0	NC*
Female	0.20	0	NC*	Female	0.21	0	NC*
Total	0.80	0	NC*	Total	0.49	0	NC*
Brain and Centra	<u>l Nervous</u>	<u>System</u>	$\underline{\mathbf{M}}$	<u>lultiple Myel</u>	<u>oma</u>		
Male	0.17	0	NC*	Male	0.11	0	NC*
Female	0.16	0	NC*	Female	0.08	0	NC*
Total	0.33	0	NC*	Total	0.19	0	NC*
Breast			No	on-Hodgkin's	<u>Lymphoma</u>	<u>1</u>	
Male	0.03	0	NC*	Male	0.40	0	NC*
Female	2.87	3	NC*	Female	0.34	0	NC*
Total	2.90	3	NC*	Total	0.74	0	NC*
Cervix Uteri			<u>O</u> :	ral Cavity an	<u>d Pharynx</u>		
				Male	0.37	0	NC*
Female	0.18	0	NC*	Female	0.15	0	NC*
				Total	0.52	0	NC*
Colon / Rectum			<u>O</u>	<u>vary</u>			
Male	1.56	2	NC*				
Female	1.35	2	NC*	Female	0.34	1	NC*
Total	2.91	4	NC*				
Esophagus			<u>Pa</u>	ancreas			
Male	0.19	1	NC*	Male	0.20	0	NC*
Female	0.07	0	NC*	Female	0.20	0	NC*
Total	0.26	1	NC*	Total	0.41	0	NC*
Hodgkin's Diseas	<u>se</u>		<u>P</u> 1	<u>rostate</u>			
Male	0.07	0	NC*	Male	3.21	2	NC*
Female	0.06	0	NC*				
Total	0.13	0	NC*				
Kidney and Rena	l Pelvis		<u>St</u>	<u>omach</u>			
Male	0.31	0	NC*	Male	0.27	0	NC*
Female	0.17	0	NC*	Female	0.15	0	NC*
Total	0.48	0	NC*	Total	0.42	0	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.20	0	NC*	Male	0.10	0	NC*
Female	0.05	0	NC*				

Total	0.24	0	NC*				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	0.22	0	NC*	Male	0.05	0	NC*
Female	0.16	0	NC*	Female	0.13	0	NC*
Total	0.38	0	NC*	Total	0.17	0	NC*
Liver and Int	rahepatic Bile D	ucts	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	0.09	0	NC*				
Female	0.04	0	NC*	Female	0.52	1	NC*
Total	0.13	0	NC*				
Lung and Bro	<u>nchus</u>		<u>A</u>]	ll Sites / Tyr	<u>oes</u>		
Male	1.75	1	NC*	Male	10.95	6	55
Female	1.03	0	NC*	Female	9.17	7	76
Total	2.78	1	NC*	Total	20.12	13	65

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases

WATERTOWN

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	\mathbf{Exp}	<u>Obs</u>	<u>SIR</u>		\mathbf{Exp}	<u>Obs</u>	<u>SIR</u>	
Bladder, Urina	<u>rv</u>		<u>M</u>	elanoma of S	<u>Skin</u>			
Male	25.77	23	89	Male	13.23	15	113	
Female	12.22	20	164	Female	13.18	11	83	
Total	37.98	43	113	Total	26.41	26	98	
Brain and Cen	tral Nervous S	<u>System</u>	<u>M</u>	ultiple Myel				
Male	8.59	10	116	Male	4.61	5	108	
Female	9.76	8	82	Female	5.36	5	93	
Total	18.35	18	98	Total	9.97	10	100	
Breast			Non-Hodgkin's Lymphoma					
Male	1.36	3	NC*	Male	19.30	26	135	
Female	183.98	193	105	Female	21.42	21	98	

^{* =} SIR and statistical significance not calculated when Obs < 5

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Total	185.34	196	106	Total	40.72	47	115
Cervix Uteri			<u>O</u> :	ral Cavity a	nd Pharynx		
				Male	16.84	16	95
Female	12.07	10	83	Female	9.40	11	117
				Total	26.24	27	103
Colon / Rectum	<u>l</u>		<u>O</u>	<u>vary</u>			
Male	68.31	77	113				
Female	82.66	105	127 #+	Female	22.12	21	95
Total	150.98	182	121 #+				
Esophagus				<u>ancreas</u>			
Male	8.51	4	NC*	Male	9.36	11	118
Female	4.08	3	NC*	Female	12.82	6	47
Total	12.59	7	56	Total	22.17	17	77
Hodgkin's Disc	<u>ease</u>		<u>Pr</u>	<u>rostate</u>			
Male	4.22	5	118	Male	152.89	189	124 ~+
Female	4.03	6	149				
Total	8.26	11	133				
Kidney and Re	enal Pelvis		St	<u>omach</u>			
Male	14.60	23	157	Male	11.33	6	53
Female	10.90	13	119	Female	9.13	13	142
Total	25.50	36	141	Total	20.47	19	93
<u>Larynx</u>			<u>Te</u>	<u>estis</u>			
Male	9.11	7	77	Male	6.69	7	105
Female	2.99	3	NC*				
Total	12.10	10	83				
Leukemia			<u>Tl</u>	<u>nyroid</u>			
Male	9.97	11	110	Male	2.59	5	193
Female	9.41	12	127	Female	8.42	11	131
Total	19.39	23	119	Total	11.01	16	145
Liver and Intra	<u>ahepatic Bile</u>	Ducts	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	4.15	8	193				
Female	2.40	1	NC*	Female	33.87	32	94
Total	6.55	9	137				
Lung and Bron	chus		<u>A</u>]	ll Sites / Ty	pes		
Male	82.52	77	93	Male	509.99	560	110 #+
Female	70.70	71	100	Female	584.88	613	105
Total	153.22	148	97	Total	1094.87	1173	107 #+

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

WAYLAND

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urina	<u>ry</u>		<u>M</u>	<u>lelanoma of</u>	<u>Skin</u>				
Male	9.91	7	71	Male	5.26	8	152		
Female	3.38	4	NC*	Female	4.07	5	123		
Total	13.29	11	83	Total	9.33	13	139		
Brain and Cent	Brain and Central Nervous System			<u>lultiple Mye</u>	<u>loma</u>				
Male	3.51	2	NC*	Male	1.82	2	NC*		
Female	3.15	0	NC*	Female	1.56	3	NC*		
Total	6.66	2	NC*	Total	3.38	5	148		
Breast			Non-Hodgkin's Lymphoma						
Male	0.54	1	NC*	Male	7.37	7	95		
Female	59.46	69	116	Female	6.12	7	114		
Total	60.00	70	117	Total	13.49	14	104		
Cervix Uteri			Oral Cavity and Pharynx						
				Male	7.39	3	NC*		
Female	3.63	4	NC*	Female	3.00	2	NC*		
				Total	10.39	5	48		
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>					
Male	26.47	19	72						
Female	22.00	20	91	Female	7.21	10	139		
Total	48.46	39	80						
Esophagus				ancreas					
Male	3.66	1	NC*	Male	3.81	5	131		
Female	1.11	2	NC*	Female	3.57	0	NC*		
Total	4.77	3	NC*	Total	7.38	5	68		
Hodgkin's Disc	ease_		<u>Pr</u>	<u>rostate</u>					
Male	1.42	1	NC*	Male	60.78	74	122		
Female	1.09	1	NC*						
Total	2.51	2	NC*						
Kidney and Re	nal Pelvis		<u>St</u>	<u>omach</u>					
Male	6.24	6	96	Male	4.33	4	NC*		
Female	3.44	1	NC*	Female	2.37	2	NC*		

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Total	9.68	7	72	Total	6.69	6	90
<u>Larynx</u>			<u>Te</u>	<u>estis</u>			
Male	4.06	0	NC*	Male	1.87	2	NC*
Female	1.09	0	NC*				
Total	5.15	0	NC*				
Leukemia			<u>Tł</u>	<u>iyroid</u>			
Male	4.01	1	NC*	Male	0.95	1	NC*
Female	2.78	2	NC*	Female	2.47	6	243
Total	6.79	3	NC*	Total	3.42	7	205
Liver and Intrahepatic Bile Ducts				t <mark>eri, Corpus</mark>	and Uterus.	NOS	
Male	1.72	1	NC*				
Female	0.69	1	NC*	Female	11.50	18	156
Total	2.42	2	NC*				
Lung and Bro	<u>nchus</u>		<u>A</u> l	ll Sites / Ty	<u>pes</u>		
Male	34.82	20	57 ~-	Male	203.81	173	85 #-
Female	22.84	19	83	Female	178.98	184	103
Total	57.66	39	68 #-	Total	382.79	357	93

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

WEBSTER

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Uri	<u>nary</u>	Melanoma of Skin							
Male	14.66	14	96	Male	6.99	4	NC*		
Female	6.09	6	99	Female	6.01	8	133		
Total	20.75	20	96	Total	12.99	12	92		
Brain and C	entral Nervous	System	Multiple Myeloma						
Male	4.51	6	133	Male	2.61	3	NC*		
Female	4.65	4	NC*	Female	2.65	2	NC*		

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Total	9.16	10	109	Total	5.26	5	95
Breast			No	on-Hodgkin	's Lymphon	<u>1a</u>	
Male	0.76	1	NC*	Male	10.21	7	69
Female	86.83	70	81	Female	10.40	7	67
Total	87.59	71	81	Total	20.60	14	68
Cervix Uteri			<u>O</u> :	ral Cavity a	nd Pharynx	_	
				Male	9.02	8	89
Female	5.22	3	NC*	Female	4.51	5	111
				Total	13.53	13	96
Colon / Rectun	<u>n</u>		<u>O</u>	<u>vary</u>			
Male	38.71	22	57 ~-				
Female	41.50	27	65 #-	Female	10.32	13	126
Total	80.20	49	61 ^-				
Esophagus			<u>Pa</u>	ancreas			
Male	4.72	2	NC*	Male	5.17	3	NC*
Female	2.05	1	NC*	Female	6.38	6	94
Total	6.77	3	NC*	Total	11.55	9	78
Hodgkin's Dis	sease_		<u>P</u> 1	<u>rostate</u>			
Male	1.99	0	NC*	Male	85.49	58	68 ~-
Female	1.75	0	NC*				
Total	3.74	0	NC*				
Kidney and Ro	enal Pelvis		St	<u>omach</u>			
Male	7.96	8	101	Male	6.43	6	93
Female	5.29	5	95	Female	4.60	3	NC*
Total	13.24	13	98	Total	11.03	9	82
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	4.96	11	222 #+	Male	2.80	7	250 #+
Female	1.42	2	NC*				
Total	6.38	13	204 #+				
<u>Leukemia</u>			<u>T</u>	<u>nyroid</u>			
Male	5.53	3	NC*	Male	1.23	0	NC*
Female	4.67	2	NC*	Female	3.62	5	138
Total	10.20	5	49	Total	4.85	5	103
Liver and Intr	ahepatic Bile	Ducts	<u>U</u> 1	<u>teri, Corpus</u>	s and Uterus	s, NOS	
Male	2.28	1	NC*				
Female	1.19	1	NC*	Female	16.08	22	137
Total	3.47	2	NC*				
Lung and Bron				ll Sites / Ty			
Male	45.53	51	112	Male	281.21	224	80 ^-
Female	34.04	28	82	Female	280.94	240	85 #-
Total	79.56	79	99	Total	562.15	464	83 ^-

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} <= 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

WELLESLEY

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR	
Bladder, Urina	<u>ry</u>		<u>M</u>	<u>lelanoma of</u>	Skin			
Male	20.67	22	106	Male	10.51	13	124	
Female	8.26	12	145	Female	9.45	8	85	
Total	28.93	34	118	Total	19.95	21	105	
Brain and Cen	tral Nervous	System	<u>M</u>	<u>lultiple Mye</u>	<u>eloma</u>			
Male	6.87	11	160	Male	3.73	8	215	
Female	7.20	10	139	Female	3.66	2	NC*	
Total	14.08	21	149	Total	7.39	10	135	
Breast			No	on-Hodgkin	's Lymphom	<u>a</u>		
Male	1.10	0	NC*	Male	14.96	11	74	
Female	132.03	168	127 ~+	Female	14.72	10	68	
Total	133.13	168	126 ~+	Total	29.68	21	71	
<u>Cervix Uteri</u>		Oral Cavity and Pharynx						
				Male	14.13	18	127	
Female	8.62	7	81	Female	6.71	5	75	
				Total	20.83	23	110	
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>				
Male	54.69	55	101					
Female	55.21	51	92	Female	16.05	21	131	
Total	109.90	106	96					
Esophagus			<u>Pa</u>	ancreas				
Male	7.13	4	NC*	Male	7.56	8	106	
Female	2.73	3	NC*	Female	8.62	11	128	
Total	9.86	7	71	Total	16.18	19	117	
Hodgkin's Dis	<u>ease</u>		<u>Pı</u>	<u>rostate</u>				
Male	2.95	3	NC*	Male	120.83	174	144 ^+	

Female	2.90	3	NC*				
Total	5.84	6	103				
Kidney and Re	enal Pelvis		<u>St</u>	Stomach			
Male	12.02	10	83	Male	9.10	10	110
Female	7.72	4	NC*	Female	6.11	5	82
Total	19.74	14	71	Total	15.21	15	99
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	7.69	5	65	Male	4.08	7	172
Female	2.21	3	NC*				
Total	9.91	8	81				
Leukemia			<u>Tl</u>	<u>hyroid</u>			
Male	8.10	9	111	Male	1.89	2	NC*
Female	6.84	7	102	Female	6.05	6	99
Total	14.94	16	107	Total	7.94	8	101
Liver and Intra	ahepatic Bile	Ducts	<u>U</u> 1	teri, Corpus	and Uterus	, NOS	
Male	3.38	3	NC*				
Female	1.65	2	NC*	Female	24.52	24	98
Total	5.03	5	99				
Lung and Bron	<u>ichus</u>		<u>A</u>]				
Male	67.31	35	52 ^-	Male	407.12	426	105
Female	49.50	37	75	Female	411.21	418	102
Total	116.81	72	62 ^-	Total	818.32	844	103

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

WELLFLEET

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary			<u>M</u>	elanoma of S	<u>Skin</u>		
Male	3.00	5	167	Male	1.36	3	NC*

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	0.94	1	NC*	Female	0.98	1	NC*	
Total	3.94	6	152	Total	2.34	4	NC*	
Brain and Cent	ral Nervous S	<u>System</u>	<u>M</u>	Multiple Myeloma				
Male	0.85	2	NC*	Male	0.53	2	NC*	
Female	0.76	3	NC*	Female	0.42	0	NC*	
Total	1.62	5	309	Total	0.96	2	NC*	
Breast			No	<u>on-Hodgkin'</u>	s Lymphoma	<u>ı</u>		
Male	0.15	0	NC*	Male	1.98	8	404 ~+	
Female	14.67	15	102	Female	1.63	2	NC*	
Total	14.82	15	101	Total	3.61	10	277 ~+	
<u>Cervix Uteri</u>			<u>O</u> :	<u>ral Cavity ar</u>	<u>nd Pharynx</u>			
				Male	1.82	1	NC*	
Female	0.84	1	NC*	Female	0.75	2	NC*	
				Total	2.57	3	NC*	
Colon / Rectum	_		<u>O</u>	<u>vary</u>				
Male	7.95	9	113					
Female	6.25	4	NC*	Female	1.74	3	NC*	
Total	14.20	13	92					
Esophagus				ancreas				
Male	0.97	0	NC*	Male	1.07	2	NC*	
Female	0.31	0	NC*	Female	1.00	2	NC*	
Total	1.29	0	NC*	Total	2.07	4	NC*	
Hodgkin's Dise			· · · · · · · · · · · · · · · · · · ·	<u>rostate</u>				
Male	0.33	0	NC*	Male	18.21	25	137	
Female	0.25	0	NC*					
Total	0.58	0	NC*					
Kidney and Re			_	omach_				
Male	1.62	4	NC*	Male	1.30	1	NC*	
Female	0.88	1	NC*	Female	0.67	1	NC*	
Total	2.51	5	199	Total	1.97	2	NC*	
<u>Larynx</u>	1.02	4		estis_	0.40	0	Mark	
Male	1.03	1	NC*	Male	0.42	0	NC*	
Female	0.26	0	NC*					
Total	1.29	1	NC*	. •1				
<u>Leukemia</u>	1.07	2		hyroid Mala	0.22	0	NOΨ	
Male	1.07	2	NC*	Male	0.22	0	NC*	
Female	0.71	2 4	NC*	Female	0.57	0	NC*	
Total	1.78		NC*	Total	0.79	0 NOS	NC*	
Liver and Intra	_		· · · · · · · · · · · · · · · · · · ·	teri, Corpus	and Uterus,	NUS_		
Male Female	0.47 0.19	1	NC* NC*	Female	2.83	2	NC*	
Total	0.19	1	NC*	remale	2.03	2	INC "	
Lung and Brone		1		ll Sites / Typ	NOC			
Male	9.55	13	136	Male	<u>57.77</u>	82	142 ~+	
Maie	7.33	13	130	iviale	31.11	04	142 ~+	

Female	5.92	11	186	Female	45.92	55	120
Total	15.47	24	155	Total	103.69	137	132 ~+

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

WENDELL

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urinary	<u>-</u>		<u>M</u>	elanoma of S	<u>Skin</u>			
Male	0.41	0	NC*	Male	0.28	0	NC*	
Female	0.13	0	NC*	Female	0.23	0	NC*	
Total	0.54	0	NC*	Total	0.52	0	NC*	
Brain and Central Nervous System			<u>M</u>	ultiple Myel	<u>oma</u>			
Male	0.20	0	NC*	Male	0.08	0	NC*	
Female	0.17	1	NC*	Female	0.06	0	NC*	
Total	0.37	1	NC*	Total	0.14	0	NC*	
Breast		Non-Hodgkin's Lymphoma						
Male	0.02	1	NC*	Male	0.40	1	NC*	
Female	2.86	6	210	Female	0.27	1	NC*	
Total	2.89	7	242	Total	0.67	2	NC*	
Cervix Uteri			<u>O</u> :	ral Cavity an	d Pharynx			
				Male	0.38	0	NC*	
Female	0.24	0	NC*	Female	0.14	0	NC*	
				Total	0.51	0	NC*	
Colon / Rectum			<u>O</u>	<u>vary</u>				
Male	1.09	0	NC*					
Female	0.82	0	NC*	Female	0.37	1	NC*	
Total	1.91	0	NC*					
Esophagus			<u>Pa</u>	ancreas				
Male	0.17	1	NC*	Male	0.16	0	NC*	

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	0.04	0	NC*	Female	0.13	0	NC*	
Total	0.21	1	NC*	Total	0.30	0	NC*	
Hodgkin's Dis	ease_		<u>P</u> 1	<u>rostate</u>				
Male	0.11	0	NC*	Male	2.22	0	NC*	
Female	0.09	0	NC*					
Total	0.20	0	NC*					
Kidney and Re	enal Pelvis		<u>St</u>	<u>omach</u>				
Male	0.30	0	NC*	Male	0.19	0	NC*	
Female	0.15	0	NC*	Female	0.09	0	NC*	
Total	0.45	0	NC*	Total	0.28	0	NC*	
<u>Larynx</u>			<u>T</u>	<u>estis</u>				
Male	0.19	0	NC*	Male	0.18	0	NC*	
Female	0.05	0	NC*					
Total	0.24	0	NC*					
Leukemia			<u>T</u>	<u>hyroid</u>				
Male	0.21	0	NC*	Male	0.07	0	NC*	
Female	0.14	0	NC*	Female	0.18	0	NC*	
Total	0.35	0	NC*	Total	0.24	0	NC*	
Liver and Intra	ahepatic Bile D	<u>Oucts</u>	<u>U</u> 1	teri, Corpus	and Uterus,	Uterus, NOS		
Male	0.08	1	NC*					
Female	0.03	0	NC*	Female	0.52	1	NC*	
Total	0.11	1	NC*					
Lung and Bron	chus		All Sites / Types					
Male	1.47	0	NC*	Male	8.91	4	NC*	
Female	0.93	1	NC*	Female	8.20	11	134	
Total	2.40	1	NC*	Total	17.11	15	88	

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

WENHAM

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases μ indicates statistical significance at the μ <= 0.05 level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urina	<u>ry</u>		$\underline{\mathbf{M}}$	<u>lelanoma of</u>	<u>Skin</u>		
Male	3.14	4	NC*	Male	1.63	7	430 ~+
Female	1.20	2	NC*	Female	1.43	0	NC*
Total	4.34	6	138	Total	3.06	7	229
Brain and Cen	<u>tral Nervous S</u>	<u>System</u>	$\underline{\mathbf{M}}$	<u>lultiple Mye</u>	<u>loma</u>		
Male	1.10	1	NC*	Male	0.57	1	NC*
Female	1.10	1	NC*	Female	0.53	1	NC*
Total	2.19	2	NC*	Total	1.10	2	NC*
Breast			<u>N</u>	<u>L</u>			
Male	0.17	2	NC*	Male	2.33	3	NC*
Female	19.41	25	129	Female	2.18	0	NC*
Total	19.57	27	138	Total	4.51	3	NC*
Cervix Uteri			<u>O</u>				
				Male	2.20	2	NC*
Female	1.34	0	NC*	Female	0.99	1	NC*
				Total	3.18	3	NC*
Colon / Rectun	<u>1</u>		<u>o</u>	<u>vary</u>			
Male	8.35	3	NC*				
Female	8.03	5	62	Female	2.38	3	NC*
Total	16.38	8	49 #-				
Esophagus			Pa	ancreas_			
Male	1.10	0	NC*	Male	1.18	0	NC*
Female	0.40	1	NC*	Female	1.26	2	NC*
Total	1.50	1	NC*	Total	2.44	2	NC*
Hodgkin's Dis	ease		Pı	<u>rostate</u>			
Male	0.48	0	NC*	Male	19.20	18	94
Female	0.48	1	NC*				
Total	0.96	1	NC*				
Kidney and Re	enal Pelvis		St	omach_			
Male	1.88	0	NC*	Male	1.37	2	NC*
Female	1.14	1	NC*	Female	0.89	1	NC*
Total	3.03	1	NC*	Total	2.26	3	NC*
<u>Larynx</u>				estis_			
Male	1.21	2	NC*	 Male	0.69	1	NC*
Female	0.32	1	NC*				
Total	1.53	3	NC*				
Leukemia			T	<u>hyroid</u>			
Male	1.27	1	NC*	Male	0.30	0	NC*
Female	1.04	0	NC*	Female	0.96	0	NC*
Total	2.31	1	NC*	Total	1.26	0	NC*
Liver and Intra					and Uterus,		. -
Male	0.53	0	NC*	,			
1.2020	2.00	· ·					

Female	0.25	1	NC*	Female	3.58	6	168
Total	0.77	1	NC*				
Lung and Bron	<u>ichus</u>		<u>A</u>]	ll Sites / Ty	<u>pes</u>		
Male	10.60	7	66	Male	63.69	61	96
Female	7.28	5	69	Female	60.68	59	97
Total	17.89	12	67	Total	124.37	120	96

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

WEST BOYLSTON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urinar	<u>v</u>		<u>M</u>	elanoma of S	<u>Skin</u>			
Male	6.55	4	NC*	Male	3.41	4	NC*	
Female	2.20	3	NC*	Female	2.23	4	NC*	
Total	8.75	7	80	Total	5.64	8	142	
Brain and Cent	ral Nervous S	<u>System</u>	<u>M</u>					
Male	2.23	4	NC*	Male	1.18	1	NC*	
Female	1.73	4	NC*	Female	0.97	0	NC*	
Total	3.96	8	202	Total	2.15	1	NC*	
Breast			Non-Hodgkin's Lymphoma					
Male	0.35	0	NC*	Male	4.92	3	NC*	
Female	32.93	30	91	Female	3.78	4	NC*	
Total	33.28	30	90	Total	8.69	7	81	
<u>Cervix Uteri</u>			<u>O</u> 1	ral Cavity an	d Pharynx			
				Male	4.45	7	157	
Female	1.92	1	NC*	Female	1.71	2	NC*	
				Total	6.16	9	146	
Colon / Rectum	_		<u>O</u>	<u>vary</u>				
Male	17.40	15	86					

^{* =} SIR and statistical significance not calculated when Obs < 5

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	14.78	15	101	Female	3.91	7	179
Total	32.18	30	93				
Esophagus			<u>Pa</u>	ancreas			
Male	2.23	2	NC*	Male	2.42	1	NC*
Female	0.74	0	NC*	Female	2.31	1	NC*
Total	2.97	2	NC*	Total	4.73	2	NC*
Hodgkin's Disc	ease		<u>P1</u>	<u>rostate</u>			
Male	1.05	0	NC*	Male	39.15	36	92
Female	0.60	0	NC*				
Total	1.65	0	NC*				
Kidney and Re	nal Pelvis		<u>St</u>	<u>omach</u>			
Male	3.82	3	NC*	Male	2.88	2	NC*
Female	1.98	2	NC*	Female	1.62	2	NC*
Total	5.81	5	86	Total	4.50	4	NC*
Larynx			<u>T</u>	<u>estis</u>			
Male	2.41	1	NC*	Male	1.61	2	NC*
Female	0.57	0	NC*				
Total	2.98	1	NC*				
Leukemia			<u>Tl</u>	<u>hyroid</u>			
Male	2.57	2	NC*	Male	0.66	0	NC*
Female	1.67	0	NC*	Female	1.30	0	NC*
Total	4.25	2	NC*	Total	1.96	0	NC*
Liver and Intra	hepatic Bile	<u>Ducts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus.	NOS	
Male	1.08	0	NC*				
Female	0.43	1	NC*	Female	6.24	11	176
Total	1.51	1	NC*				
Lung and Bron	<u>chus</u>		<u>A</u>]	ll Sites / Ty	<u>pes</u>		
Male	21.49	14	65	Male	131.05	109	83
Female	13.00	8	62	Female	104.44	102	98
Total	34.49	22	64 #-	Total	235.49	211	90

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

WEST BRIDGEWATER

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	SIR	
Bladder, Urina	<u>ry</u>		<u>M</u>	<u>lelanoma of</u>	<u>Skin</u>			
Male	5.51	7	127	Male	2.81	2	NC*	
Female	2.05	1	NC*	Female	2.27	3	NC*	
Total	7.56	8	106	Total	5.08	5	98	
Brain and Cent	tral Nervous	<u>System</u>	<u>M</u>	<u>ultiple Mye</u>	<u>loma</u>			
Male	1.86	0	NC*	Male	1.00	0	NC*	
Female	1.77	1	NC*	Female	0.93	1	NC*	
Total	3.63	1	NC*	Total	1.93	1	NC*	
Breast			No	<u>on-Hodgkin'</u>	s Lymphoma	<u>ı</u>		
Male	0.29	0	NC*	Male	4.02	3	NC*	
Female	33.04	29	88	Female	3.65	3	NC*	
Total	33.34	29	87	Total	7.67	6	78	
Cervix Uteri			Oral Cavity and Pharynx					
				Male	3.78	3	NC*	
Female	2.03	4	NC*	Female	1.68	0	NC*	
				Total	5.47	3	NC*	
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>				
Male	14.66	14	95					
Female	13.64	8	59	Female	3.98	5	126	
Total	28.30	22	78					
Esophagus			<u>Pa</u>	ancreas				
Male	1.91	0	NC*	Male	2.05	2	NC*	
Female	0.68	0	NC*	Female	2.18	6	276 #+	
Total	2.60	0	NC*	Total	4.22	8	189	
Hodgkin's Disc	ease_		<u>P</u> 1	<u>rostate</u>				
Male	0.80	0	NC*	Male	33.32	26	78	
Female	0.65	2	NC*					
Total	1.45	2	NC*					
Kidney and Re	nal Pelvis		<u>St</u>	<u>omach</u>				
Male	3.27	1	NC*	Male	2.41	1	NC*	
Female	1.97	5	253	Female	1.47	1	NC*	
Total	5.24	6	114	Total	3.88	2	NC*	
<u>Larynx</u>			<u>Te</u>	<u>estis</u>				
Male	2.08	1	NC*	Male	1.11	0	NC*	
Female	0.58	3	NC*					
Total	2.66	4	NC*					
Leukemia			<u>Tl</u>	<u>nyroid</u>				

Male	2.18	0	NC*	Male	0.51	0	NC*
Female	1.63	1	NC*	Female	1.39	0	NC*
Total	3.82	1	NC*	Total	1.90	0	NC*
Liver and Intra	and Intrahepatic Bile Ducts <u>Uteri, Corpus and Uterus, NOS</u>						
Male	0.92	1	NC*				
Female	0.42	1	NC*	Female	6.31	7	111
Total	1.33	2	NC*				
Lung and Bron	<u>ichus</u>		<u>A</u> l	l Sites / Ty	pes		
Male	18.43	23	125	Male	110.57	89	80 #-
Female	13.06	14	107	Female	102.82	103	100
Total	31.49	37	117	Total	213.39	192	90

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} <= 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

WEST BROOKFIELD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		\mathbf{Exp}	<u>Obs</u>	<u>SIR</u>	
Bladder, Urinar	<u>v</u>		<u>M</u>	<u>lelanoma of S</u>	<u>Skin</u>			
Male	3.23	2	NC*	Male	1.55	2	NC*	
Female	1.37	1	NC*	Female	1.34	0	NC*	
Total	4.59	3	NC*	Total	2.89	2	NC*	
Brain and Cent	ral Nervous S	ervous System Multiple Myeloma						
Male	0.99	1	NC*	Male	0.57	0	NC*	
Female	1.02	0	NC*	Female	0.59	0	NC*	
Total	2.02	1	NC*	Total	1.16	0	NC*	
Breast			<u>N</u>	on-Hodgkin's	s Lymphoma	<u>a</u>		
Male	0.17	0	NC*	Male	2.22	4	NC*	
Female	19.46	20	103	Female	2.30	2	NC*	
Total	19.63	20	102	Total	4.52	6	133	
Cervix Uteri			<u>O</u>	ral Cavity an	d Pharynx			

^{* =} SIR and statistical significance not calculated when Obs < 5

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

				Male	2.07	0	NC*
Female	1.14	3	NC*	Female	1.02	0	NC*
Temale	1.14	3	INC.	Total	3.09	0	NC*
Colon / Doctum			0		3.09	U	NC.
Colon / Rectum	_	O		<u>vary</u>			
Male	8.48	8	94 75	г 1	2.20	2	NOΨ
Female	9.30	7	75	Female	2.30	2	NC*
Total	17.78	15	84				
Esophagus				ancreas			
Male	1.07	1	NC*	Male	1.14	1	NC*
Female	0.46	0	NC*	Female	1.41	0	NC*
Total	1.53	1	NC*	Total	2.55	1	NC*
Hodgkin's Dis	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Male	0.41	2	NC*	Male	18.44	23	125
Female	0.36	0	NC*				
Total	0.77	2	NC*				
Kidney and Re	enal Pelvis		St	omach_			
Male	1.77	2	NC*	Male	1.42	0	NC*
Female	1.16	1	NC*	Female	1.05	1	NC*
Total	2.93	3	NC*	Total	2.47	1	NC*
<u>Larynx</u>				estis			
Male	1.14	0	NC*	Male	0.54	1	NC*
Female	0.32	2	NC*				
Total	1.46	2	NC*				
<u>Leukemia</u>	11.10	_		<u>hyroid</u>			
Male	1.21	0	NC*	Male	0.26	0	NC*
Female	1.04	1	NC*	Female	0.78	1	NC*
Total	2.26	1	NC*	Total	1.04	1	NC*
Liver and Intra					and Uterus.		NC
Male	0.50	0	NC*	cer, corpus	and oterus.	1105	
		0	NC*	Eomolo	3.59	3	NC*
Female	0.26			Female	3.39	3	NC.
Total	0.77	0	NC*	U G'4 / / / / / / / / / / / / / / / / / / /			
Lung and Bron		2	_	ll Sites / Ty		<i>7</i> 2	0.6
Male	10.05	3	NC*	Male	61.55	53	86
Female	7.31	2	NC*	Female	62.45	54	86
Total	17.37	5	29 ~-	Total	124.00	107	86

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

WEST NEWBURY

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		$\mathbf{\underline{Exp}}$	<u>Obs</u>	<u>SIR</u>		
Bladder, Urinar	<u>'Y</u>		<u>M</u>	elanoma of	<u>Skin</u>				
Male	2.24	2	NC*	Male	1.29	0	NC*		
Female	0.72	1	NC*	Female	1.01	1	NC*		
Total	2.96	3	NC*	Total	2.30	1	NC*		
Brain and Cent	ral Nervous	<u>System</u>	<u>M</u>	<u>[ultiple Mye</u>	<u>loma</u>				
Male	0.90	1	NC*	Male	0.41	1	NC*		
Female	0.77	1	NC*	Female	0.34	0	NC*		
Total	1.67	2	NC*	Total	0.75	1	NC*		
Breast			<u>N</u>	<u>on-Hodgkin'</u>	s Lymphoma	<u>1</u>			
Male	0.13	0	NC*	Male	1.81	2	NC*		
Female	13.81	12	87	Female	1.38	2	NC*		
Total	13.93	12	86	Total	3.19	4	NC*		
<u>Cervix Uteri</u>			Oral Cavity and Pharynx						
				Male	1.78	1	NC*		
Female	0.96	0	NC*	Female	0.68	1	NC*		
				Total	2.46	2	NC*		
Colon / Rectum	_		<u>O</u>	<u>vary</u>					
Male	5.95	3	NC*						
Female	4.65	2	NC*	Female	1.72	3	NC*		
Total	10.61	5	47						
Esophagus			<u>Pa</u>	ancreas					
Male	0.85	2	NC*	Male	0.87	2	NC*		
Female	0.23	1	NC*	Female	0.76	0	NC*		
Total	1.08	3	NC*	Total	1.63	2	NC*		
Hodgkin's Dise	<u>ease</u>		<u>P</u> 1	<u>rostate</u>					
Male	0.41	0	NC*	Male	13.13	16	122		
Female	0.32	0	NC*						
Total	0.73	0	NC*						
Kidney and Re	<u>nal Pelvis</u>		<u>St</u>	omach_					
Male	1.46	1	NC*	Male	1.00	1	NC*		
Female	0.78	0	NC*	Female	0.50	0	NC*		
Total	2.24	1	NC*	Total	1.50	1	NC*		
<u>Larynx</u>			<u>Te</u>	<u>estis</u>					

[~] indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	0.95	1	NC*	Male	0.59	0	NC*
Female	0.24	0	NC*				
Total	1.19	1	NC*				
Leukemia			<u>Tl</u>	<u>nyroid</u>			
Male	0.99	2	NC*	Male	0.26	0	NC*
Female	0.67	0	NC*	Female	0.68	1	NC*
Total	1.66	2	NC*	Total	0.93	1	NC*
Liver and Intr	ahepatic Bile I	<u>U</u> 1	teri, Corpus	and Uterus,	NOS_		
Male	0.40	0	NC*				
Female	0.15	0	NC*	Female	2.61	1	NC*
Total	0.55	0	NC*				
Lung and Bron	<u>nchus</u>		<u>A</u>]	ll Sites / Typ	<u>oes</u>		
Male	7.83	7	89	Male	46.59	44	94
Female	5.07	4	NC*	Female	40.84	31	76
Total	12.90	11	85	Total	87.43	75	86

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

WEST SPRINGFIELD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	SIR
Bladder, Urina	<u>ry</u>		$\underline{\mathbf{M}}$	<u>lelanoma of</u>			
Male	23.00	23	100	Male	11.73	8	68
Female	9.16	12	131	Female	9.77	5	51
Total	32.16	35	109	Total	21.50	13	60
Brain and Central Nervous System			Multiple Myeloma				
Male	7.77	8	103	Male	4.15	3	NC*
Female	7.51	10	133	Female	4.05	3	NC*
Total	15.28	18	118	Total	8.20	6	73
Breast			N	on-Hodgkin'	s Lymphoma)	

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	1.22	1	NC*	Male	16.92	12	71
Female	140.44	123	88	Female	16.00	20	125
Total	141.66	124	88	Total	32.92	32	97
Cervix Uteri	111100				nd Pharynx		, ,
<u>COLVIN COLL</u>			<u> </u>	Male	15.56	14	90
Female	8.68	4	NC*	Female	7.21	5	69
2 01110110	0.00	·	1,0	Total	22.77	19	83
Colon / Rectur	<u>n</u> _		O	vary_			
Male	– 61.18	58	95	 _			
Female	61.52	53	86	Female	16.85	17	101
Total	122.70	111	90				
Esophagus			<u>Pa</u>	ncreas			
Male	7.88	4	NC*	Male	8.50	9	106
Female	3.05	0	NC*	Female	9.62	13	135
Total	10.93	4	NC*	Total	18.12	22	121
Hodgkin's Di	<u>sease</u>		<u>Pı</u>	<u>costate</u>			
Male	3.48	7	201	Male	138.83	128	92
Female	2.83	4	NC*				
Total	6.31	11	174				
Kidney and R	enal Pelvis		St	<u>omach</u>			
Male	13.48	8	59	Male	10.07	10	99
Female	8.37	7	84	Female	6.76	7	104
Total	21.85	15	69	Total	16.83	17	101
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	8.53	9	105	Male	5.02	4	NC*
Female	2.38	5	211				
Total	10.91	14	128				
Leukemia			<u>Tl</u>	<u>nyroid</u>			
Male	9.10	9	99	Male	2.18	2	NC*
Female	7.20	8	111	Female	6.00	7	117
Total	16.30	17	104	Total	8.18	9	110
Liver and Inti	ahepatic Bile	<u>Ducts</u>	<u>U</u> 1	t <mark>eri, Corpus</mark>	and Uterus	s, NOS	
Male	3.79	3	NC*				
Female	1.82	2	NC*	Female	26.33	22	84
Total	5.61	5	89				
Lung and Bro	<u>nchus</u>		<u>A</u>]	ll Sites / Ty			
Male	76.12	83	109	Male	460.50	436	95
Female	54.47	54	99	Female	443.05	412	93
Total	130.59	137	105	Total	903.55	848	94

 $\mathbf{Exp} = \text{expected case count}$, based on the Massachusetts average age-specific incidence rates for this cancer $\mathbf{Obs} = \text{observed case count}$

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} <= 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

WEST STOCKBRIDGE

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	$\mathbf{\underline{Exp}}$	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urinar	<u>v</u>		<u>M</u>	<u>lelanoma of S</u>	<u>Skin</u>				
Male	1.63	1	NC*	Male	0.74	1	NC*		
Female	0.43	1	NC*	Female	0.50	0	NC*		
Total	2.06	2	NC*	Total	1.24	1	NC*		
Brain and Cent	ral Nervous S	<u>System</u>	<u>M</u>	<u>ultiple Myel</u>	<u>oma</u>				
Male	0.47	0	NC*	Male	0.29	0	NC*		
Female	0.39	1	NC*	Female	0.20	0	NC*		
Total	0.86	1	NC*	Total	0.49	0	NC*		
Breast			Non-Hodgkin's Lymphoma						
Male	0.08	0	NC*	Male	1.08	0	NC*		
Female	7.15	7	98	Female	0.78	0	NC*		
Total	7.24	7	97	Total	1.85	0	NC*		
Cervix Uteri			Oral Cavity and Pharynx						
				Male	0.98	0	NC*		
Female	0.46	1	NC*	Female	0.36	0	NC*		
				Total	1.34	0	NC*		
Colon / Rectum	_		<u>O</u>	<u>vary</u>					
Male	4.33	4	NC*						
Female	2.82	0	NC*	Female	0.87	0	NC*		
Total	7.15	4	NC*						
Esophagus			<u>Pa</u>	ancreas_					
Male	0.53	0	NC*	Male	0.58	1	NC*		
Female	0.14	0	NC*	Female	0.46	0	NC*		
Total	0.67	0	NC*	Total	1.04	1	NC*		
Hodgkin's Dise	<u>ease</u>		<u>Pı</u>	<u>rostate</u>					
Male	0.18	0	NC*	Male	9.91	5	50		
Female	0.15	0	NC*						
Total	0.33	0	NC*						

Kidney and Re	nal Pelvis		St	<u>omach</u>			
Male	0.89	1	NC*	Male	0.71	0	NC*
Female	0.43	0	NC*	Female	0.30	0	NC*
Total	1.31	1	NC*	Total	1.01	0	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.55	0	NC*	Male	0.23	0	NC*
Female	0.13	0	NC*				
Total	0.68	0	NC*				
<u>Leukemia</u>			<u>Tl</u>	<u>nyroid</u>			
Male	0.59	0	NC*	Male	0.12	0	NC*
Female	0.35	0	NC*	Female	0.32	0	NC*
Total	0.94	0	NC*	Total	0.43	0	NC*
Liver and Intra	<u>hepatic Bile D</u>	<u>Oucts</u>	<u>U</u> 1	teri, Corpus	and Uterus,	NOS_	
Male	0.25	0	NC*				
Female	0.09	0	NC*	Female	1.37	1	NC*
Total	0.34	0	NC*				
Lung and Bron	<u>chus</u>		<u>A</u>]	ll Sites / Typ	<u>oes</u>		
Male	5.20	1	NC*	Male	31.45	14	45 ^-
Female	2.84	2	NC*	Female	22.06	17	77
Total	8.04	3	NC*	Total	53.50	31	58 ~-

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

WEST TISBURY

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary	_		<u>M</u>	<u>lelanoma of S</u>	<u>Skin</u>		
Male	1.33	0	NC*	Male	0.72	0	NC*
Female	0.36	0	NC*	Female	0.52	2	NC*
Total	1.69	0	NC*	Total	1.24	2	NC*

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Brain and Central Nervous System				Multiple Myeloma					
Male	0.49	0	NC*	Male	0.24	0	NC*		
Female	0.40	0	NC*	Female	0.17	0	NC*		
Total	0.89	0	NC*	Total	0.41	0	NC*		
Breast			<u>N</u>	on-Hodgkin'	s Lymphoma	<u>1</u>			
Male	0.07	0	NC*	Male	1.02	0	NC*		
Female	6.89	5	73	Female	0.70	3	NC*		
Total	6.97	5	72	Total	1.73	3	NC*		
Cervix Uteri			<u>O</u>	ral Cavity a	nd Pharynx				
				Male	0.96	1	NC*		
Female	0.51	1	NC*	Female	0.34	1	NC*		
				Total	1.31	2	NC*		
Colon / Rectum			<u>O</u>	<u>vary</u>					
Male	3.50	2	NC*						
Female	2.30	4	NC*	Female	0.87	0	NC*		
Total	5.80	6	103						
Esophagus			<u>Pa</u>	ancreas					
Male	0.47	0	NC*	Male	0.49	0	NC*		
Female	0.12	0	NC*	Female	0.38	0	NC*		
Total	0.59	0	NC*	Total	0.87	0	NC*		
Hodgkin's Dise	<u>ase</u>		<u>P</u> 1	rostate					
Male	0.23	0	NC*	Male	7.56	5	66		
Female	0.18	0	NC*						
Total	0.41	0	NC*						
Kidney and Ren	<u>nal Pelvis</u>		St	omach_					
Male	0.80	0	NC*	Male	0.59	0	NC*		
Female	0.40	0	NC*	Female	0.25	0	NC*		
Total	1.20	0	NC*	Total	0.84	0	NC*		
<u>Larynx</u>			<u>T</u>	<u>estis</u>					
Male	0.51	0	NC*	Male	0.33	0	NC*		
Female	0.12	0	NC*						
Total	0.63	0	NC*						
Leukemia				<u>hyroid</u>					
Male	0.56	1	NC*	Male	0.14	0	NC*		
Female	0.34	0	NC*	Female	0.36	0	NC*		
Total	0.91	1	NC*	Total	0.50	0	NC*		
Liver and Intra	_	<u>ucts</u>	· · · · · · · · · · · · · · · · · · ·	<u>teri, Corpus</u>	and Uterus,	NOS_			
Male	0.22	1	NC*						
Female	0.08	0	NC*	Female	1.31	0	NC*		
Total	0.30	1	NC*						
Lung and Brone				ll Sites / Typ					
Male	4.35	1	NC*	Male	26.53	11	41 ~-		
Female	2.57	2	NC*	Female	20.57	18	88		
Total	6.92	3	NC*	Total	47.10	29	62 ~-		

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

WESTBOROUGH

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	\mathbf{Exp}	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urina	<u>ry</u>		<u>M</u>	elanoma of	<u>Skin</u>				
Male	10.62	7	66	Male	5.74	4	NC*		
Female	4.45	4	NC*	Female	4.91	0	NC*		
Total	15.07	11	73	Total	10.65	4	NC*		
Brain and Central Nervous System			<u>M</u>	ultiple Mye					
Male	3.82	3	NC*	Male	1.92	3	NC*		
Female	3.69	5	136	Female	1.95	3	NC*		
Total	7.51	8	107	Total	3.87	6	155		
Breast		Non-Hodgkin's Lymphoma							
Male	0.57	1	NC*	Male	8.20	7	85		
Female	68.36	68	99	Female	7.82	6	77		
Total	68.94	69	100	Total	16.02	13	81		
<u>Cervix Uteri</u>			Oral Cavity and Pharynx						
				Male	7.48	4	NC*		
Female	4.46	6	135	Female	3.48	3	NC*		
				Total	10.96	7	64		
Colon / Rectun	<u>n</u> _		<u>O</u>	<u>vary</u>					
Male	27.99	19	68						
Female	30.08	19	63 #-	Female	8.27	4	NC*		
Total	58.07	38	65 ~-						
Esophagus			<u>Pa</u>	ancreas					
Male	3.67	4	NC*	Male	3.87	6	155		
Female	1.47	1	NC*	Female	4.63	4	NC*		
Total	5.15	5	97	Total	8.50	10	118		

SIR = standardized incidence ratio [$(Obs / Exp) \times 100$]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Hodgkin's Dis	Hodgkin's Disease				Prostate			
Male	1.85	2	NC*	Male	59.66	43	72 #-	
Female	1.50	2	NC*					
Total	3.36	4	NC*					
Kidney and R	enal Pelvis		<u>St</u>	Stomach				
Male	6.25	5	80	Male	4.74	3	NC*	
Female	3.99	4	NC*	Female	3.37	1	NC*	
Total	10.24	9	88	Total	8.10	4	NC*	
<u>Larynx</u>			<u>Testis</u>					
Male	3.95	3	NC*	Male	2.82	1	NC*	
Female	1.11	0	NC*					
Total	5.06	3	NC*					
Leukemia			<u>Tł</u>	<u>iyroid</u>				
Male	4.36	2	NC*	Male	1.13	2	NC*	
Female	3.60	1	NC*	Female	3.13	0	NC*	
Total	7.96	3	NC*	Total	4.26	2	NC*	
Liver and Intr	ahepatic Bile	<u>Ducts</u>	<u>Uteri, Corpus and Uterus, NOS</u>					
Male	1.75	0	NC*					
Female	0.87	0	NC*	Female	12.52	12	96	
Total	2.62	0	NC*					
Lung and Bronchus			All Sites / Types					
Male	33.98	25	74	Male	209.66	161	77 ^-	
Female	25.32	20	79	Female	215.29	175	81 ~-	
Total	59.30	45	76	Total	424.95	336	79 ^-	

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

WESTFIELD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

<u>Exp</u> <u>Obs</u> <u>SIR</u> <u>Exp</u> <u>Obs</u> <u>SIR</u>

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Bladder, Urina	<u>ry</u>	Melanoma of Skin					
Male	27.84	34	122	Male	14.62	13	89
Female	10.93	14	128	Female	12.52	17	136
Total	38.77	48	124	Total	27.15	30	111
Brain and Cen	tral Nervous	System	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>		
Male	9.92	10	101	Male	5.03	3	NC*
Female	9.63	10	104	Female	4.84	9	186
Total	19.56	20	102	Total	9.87	12	122
Breast			<u>N</u>	on-Hodgkin'	s Lymphoma	_	
Male	1.49	1	NC*	Male	21.21	14	66
Female	173.18	174	100	Female	19.60	13	66
Total	174.67	175	100	Total	40.81	27	66 #-
Cervix Uteri			<u>O</u>	ral Cavity aı	nd Pharynx		
				Male	19.05	14	74
Female	11.56	9	78	Female	8.81	4	NC*
				Total	27.86	18	65
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	73.93	77	104				
Female	73.26	69	94	Female	21.12	21	99
Total	147.19	146	99				
Esophagus			<u>Pa</u>	ancreas			
Male	9.52	10	105	Male	10.27	10	97
Female	3.63	0	NC*	Female	11.46	6	52
Total	13.14	10	76	Total	21.73	16	74
Hodgkin's Dis	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Male	4.75	4	NC*	Male	165.34	133	80 #-
Female	4.04	5	124				
Total	8.79	9	102				
Kidney and Re	enal Pelvis		<u>St</u>	<u>omach</u>			
Male	16.43	13	79	Male	12.25	7	57
Female	10.25	13	127	Female	8.07	8	99
Total	26.68	26	97	Total	20.32	15	74
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	10.29	12	117	Male	7.07	6	85
Female	2.88	4	NC*				
Total	13.16	16	122				
<u>Leukemia</u>			<u>T</u>	<u>hyroid</u>			
Male	11.46	10	87	Male	2.86	2	NC*
Female	9.19	8	87	Female	8.19	4	NC*
Total	20.64	18	87	Total	11.05	6	54
Liver and Intra	ahepatic Bile	Ducts	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	4.62	5	108				
Female	2.21	1	NC*	Female	32.07	36	112
Total	6.83	6	88				

Lung and Bronchus			All Sites / Types				
Male	91.39	100	109	Male	559.18	499	89 #-
Female	65.66	53	81	Female	543.49	515	95
Total	157.04	153	97	Total	1102.68	1014	92 ~-

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

WESTFORD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urinar	<u>y</u> _		<u>M</u>	elanoma of	<u>Skin</u>			
Male	9.68	5	52	Male	5.95	7	118	
Female	3.21	0	NC*	Female	4.69	9	192	
Total	12.89	5	39 #-	Total	10.64	16	150	
Brain and Cent	ral Nervous	<u>System</u>	<u>M</u>	ultiple Mye	<u>loma</u>			
Male	4.21	2	NC*	Male	1.80	3	NC*	
Female	3.55	3	NC*	Female	1.49	2	NC*	
Total	7.76	5	64	Total	3.29	5	152	
Breast			Non-Hodgkin's Lymphoma					
Male	0.55	1	NC*	Male	8.33	7	84	
Female	62.46	71	114	Female	6.27	4	NC*	
Total	63.01	72	114	Total	14.60	11	75	
<u>Cervix Uteri</u>			<u>O</u> 1	ral Cavity ar	nd Pharynx			
				Male	8.09	3	NC*	
Female	4.57	9	197	Female	3.06	5	163	
				Total	11.15	8	72	
Colon / Rectum	1	<u>Ovary</u>						
Male	25.78	15	58 #-					
Female	20.70	20	97	Female	7.86	8	102	
Total	46.48	35	75					

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Esophagus			<u>Pa</u>	ancreas				
Male	3.76	0	NC*	Male	3.82	2	NC*	
Female	1.03	1	NC*	Female	3.37	1	NC*	
Total	4.79	1	NC*	Total	7.20	3	NC*	
Hodgkin's Dis	sease_		<u>Pr</u>	<u>rostate</u>				
Male	2.08	1	NC*	Male	56.35	55	98	
Female	1.58	3	NC*					
Total	3.66	4	NC*					
Kidney and Ro	<u>enal Pelvis</u>		<u>St</u>	<u>omach</u>				
Male	6.57	6	91	Male	4.32	3	NC*	
Female	3.49	4	NC*	Female	2.25	1	NC*	
Total	10.06	10	99	Total	6.57	4	NC*	
<u>Larynx</u>			<u>Te</u>	<u>estis</u>				
Male	4.22	1	NC*	Male	3.14	4	NC*	
Female	1.09	0	NC*					
Total	5.31	1	NC*					
<u>Leukemia</u>			<u>Tl</u>	<u>nyroid</u>				
Male	4.50	5	111	Male	1.26	4	NC*	
Female	3.09	4	NC*	Female	3.27	4	NC*	
Total	7.59	9	119	Total	4.54	8	176	
Liver and Intr	<u>ahepatic Bile</u>	<u>Ducts</u>		<u>Iteri, Corpus and Uterus, NOS</u>				
Male	1.79	1	NC*					
Female	0.69	1	NC*	Female	11.69	6	51	
Total	2.47	2	NC*					
Lung and Bron	Lung and Bronchus Al			ll Sites / Ty	<u>pes</u>			
Male	34.48	33	96	Male	205.84	167	81 ~-	
Female	22.45	18	80	Female	184.49	183	99	
Total	56.94	51	90	Total	390.33	350	90 #-	

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

WESTHAMPTON

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Cancer Incidence by Sex, 1990 - 1995 Expected and Observed Case Counts, with Standardized Incidence Ratios

Female 0.23 0 NC* Female 0.35 0 NC Total 1.09 0 NC* Total 0.85 0 NC Brain and Central Nervous System Multiple Myeloma	NC* NC* NC* NC* NC*
Female 0.23 0 NC* Female 0.35 0 NC Total 1.09 0 NC* Total 0.85 0 NC Brain and Central Nervous System Multiple Myeloma	NC* NC* NC* NC*
Total 1.09 0 NC* Total 0.85 0 NC Brain and Central Nervous System Multiple Myeloma	NC* NC* NC*
Brain and Central Nervous System Multiple Myeloma	NC* NC*
	VC*
	VC*
Male 0.35 0 NC* Male 0.16 0 NC	
Female 0.27 1 NC* Female 0.11 1 NC	1C*
Total 0.62 1 NC* Total 0.27 1 NC	, _
<u>Non-Hodgkin's Lymphoma</u>	
Male 0.05 0 NC* Male 0.70 0 NC	$^{1}C^{*}$
Female 4.65 9 194 Female 0.47 0 NC	$^{1}C^{*}$
Total 4.69 9 192 Total 1.17 0 NC	$^{1}C^{*}$
<u>Cervix Uteri</u> <u>Oral Cavity and Pharynx</u>	
Male 0.67 0 NO	$^{1}C^{*}$
Female 0.35 0 NC* Female 0.23 0 NC	$^{1}C^{*}$
Total 0.89 0 NC	VC*
<u>Colon / Rectum</u> <u>Ovary</u>	
Male 2.27 1 NC*	
Female 1.51 0 NC* Female 0.59 0 NC	VC*
Total 3.78 1 NC*	
Esophagus Pancreas	
Male 0.32 0 NC* Male 0.33 0 NC	VC*
Female 0.08 0 NC* Female 0.25 0 NC	VC*
Total 0.39 0 NC* Total 0.58 0 NC	VC*
Hodgkin's Disease Prostate	
Male 0.17 1 NC* Male 5.01 1 NC	VC*
Female 0.13 0 NC*	
Total 0.30 1 NC*	
Kidney and Renal Pelvis Stomach	
Male 0.55 1 NC* Male 0.38 0 NC	VC*
Female 0.26 0 NC* Female 0.16 0 NC	NC*
Total 0.81 1 NC* Total 0.54 0 NC	VC*
<u>Larynx</u> <u>Testis</u>	
Male 0.35 0 NC* Male 0.25 0 NC	$^{1}C^{*}$
Female 0.08 0 NC*	
Total 0.43 0 NC*	
<u>Leukemia</u> <u>Thyroid</u>	
Male 0.38 0 NC* Male 0.10 0 NC	VC*
Female 0.23 0 NC* Female 0.25 0 NC	VC*

Total	0.62	0	NC*	Total	0.36	0	NC*	
Liver and Intrahepatic Bile Ducts			<u>Uteri, Corpus and Uterus, NOS</u>					
Male	0.15	0	NC*					
Female	0.05	0	NC*	Female	0.87	1	NC*	
Total	0.20	0	NC*					
Lung and Brond	<u>chus</u>		All Sites / Types					
Male	2.95	1	NC*	Male	17.79	6	34 ~-	
Female	1.68	2	NC*	Female	13.72	15	109	
Total	4.63	3	NC*	Total	31.52	21	67	

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

WESTMINSTER

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		\mathbf{Exp}	<u>Obs</u>	<u>SIR</u>		
Bladder, Urina	<u>ry</u>		<u>M</u>	elanoma of	<u>Skin</u>				
Male	4.32	4	NC*	Male	2.43	1	NC*		
Female	1.44	2	NC*	Female	1.90	0	NC*		
Total	5.76	6	104	Total	4.33	1	NC*		
Brain and Cent	tral Nervous S	<u>System</u>	<u>M</u>	ultiple Mye	<u>loma</u>				
Male	1.66	0	NC*	Male	0.80	1	NC*		
Female	1.46	1	NC*	Female	0.66	0	NC*		
Total	3.12	1	NC*	Total	1.45	1	NC*		
Breast			<u>N</u>	on-Hodgkin'	s Lymphoma	<u>1</u>			
Male	0.24	0	NC*	Male	3.47	6	173		
Female	25.75	20	78	Female	2.71	3	NC*		
Total	25.99	20	77	Total	6.18	9	146		
Cervix Uteri		Oral Cavity and Pharynx							
				Male	3.23	4	NC*		
Female	1.82	4	NC*	Female	1.28	1	NC*		

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

				Total	4.51	5	111	
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>				
Male	11.50	11	96					
Female	9.38	5	53	Female	3.20	3	NC*	
Total	20.88	16	77					
Esophagus			<u>Pa</u>	<u>ancreas</u>				
Male	1.56	2	NC*	Male	1.64	0	NC*	
Female	0.47	0	NC*	Female	1.52	1	NC*	
Total	2.03	2	NC*	Total	3.16	1	NC*	
<u>Hodgkin's Dis</u>	<u>ease</u>		<u>P</u> 1	Prostate				
Male	0.80	0	NC*	Male	25.35	20	79	
Female	0.64	0	NC*					
Total	1.44	0	NC*					
Kidney and Re	enal Pelvis		St	<u>omach</u>				
Male	2.71	1	NC*	Male	1.91	4	NC*	
Female	1.49	0	NC*	Female	1.01	0	NC*	
Total	4.20	1	NC*	Total	2.93	4	NC*	
<u>Larynx</u>			<u>T</u>	<u>estis</u>				
Male	1.71	2	NC*	Male	1.21	0	NC*	
Female	0.45	0	NC*					
Total	2.16	2	NC*					
Leukemia			<u>Tl</u>	<u>nyroid</u>				
Male	1.85	0	NC*	Male	0.49	0	NC*	
Female	1.30	1	NC*	Female	1.29	1	NC*	
Total	3.15	1	NC*	Total	1.79	1	NC*	
Liver and Intra	ahepatic Bile	<u>Ducts</u>	<u>U</u> 1	teri, Corpus	and Uterus,	NOS_		
Male	0.75	3	NC*					
Female	0.30	0	NC*	Female	4.84	5	103	
Total	1.05	3	NC*					
<u>Lung and Bronchus</u> <u>All Sites / Types</u>								
Male	14.70	7	48 #-	Male	88.75	73	82	
Female	9.68	9	93	Female	78.07	65	83	
Total	24.38	16	66	Total	166.82	138	83 #-	

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

WESTON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urina	<u>ry</u>		<u>M</u>	<u>lelanoma of</u>	<u>Skin</u>		
Male	10.16	10	98	Male	5.08	7	138
Female	3.39	1	NC*	Female	3.95	4	NC*
Total	13.55	11	81	Total	9.03	11	122
Brain and Cent	tral Nervous	<u>System</u>	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>		
Male	3.25	6	184	Male	1.84	3	NC*
Female	2.98	3	NC*	Female	1.53	1	NC*
Total	6.24	9	144	Total	3.37	4	NC*
Breast			No	<u>on-Hodgkin'</u>	s Lymphoma	<u>ı</u>	
Male	0.54	1	NC*	Male	7.13	4	NC*
Female	56.66	58	102	Female	6.06	5	83
Total	57.20	59	103	Total	13.18	9	68
<u>Cervix Uteri</u>			<u>O</u> 1	ral Cavity aı	<u>nd Pharynx</u>		
				Male	7.08	2	NC*
Female	3.55	0	NC*	Female	2.86	5	175
				Total	9.94	7	70
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>			
Male	26.99	19	70				
Female	22.41	28	125	Female	6.86	7	102
Total	49.40	47	95				
Esophagus			<u>Pa</u>	ancreas			
Male	3.60	0	NC*	Male	3.78	3	NC*
Female	1.12	2	NC*	Female	3.55	5	141
Total	4.71	2	NC*	Total	7.33	8	109
Hodgkin's Disc	<u>ease</u>		<u>Pı</u>	<u>rostate</u>			
Male	1.24	1	NC*	Male	61.03	92	151 ^+
Female	1.10	0	NC*				
Total	2.33	1	NC*				
Kidney and Re	nal Pelvis		St	<u>omach</u>			
Male	6.02	4	NC*	Male	4.44	1	NC*
Female	3.26	2	NC*	Female	2.46	1	NC*
Total	9.28	6	65	Total	6.90	2	NC*
<u>Larynx</u>			<u>Te</u>	<u>estis</u>			
Male	3.92	1	NC*	Male	1.57	2	NC*

Female	0.99	0	NC*				
Total	4.91	1	NC*				
Leukemia			<u>T</u>	<u>nyroid</u>			
Male	3.85	6	156	Male	0.86	1	NC*
Female	2.74	7	256 #+	Female	2.44	4	NC*
Total	6.59	13	197 #+	Total	3.30	5	152
Liver and Intrahepatic Bile Ducts			<u>Uteri, Corpus and Uterus, NOS</u>				
Male	1.68	0	NC*				
Female	0.68	0	NC*	Female	10.72	9	84
Total	2.36	0	NC*				
Lung and Bron	<u>nchus</u>		<u>A</u> l	ll Sites / Ty	<u>pes</u>		
Male	34.14	21	62 #-	Male	201.82	201	100
Female	21.31	11	52 #-	Female	173.05	163	94
Total	55.45	32	58 ^-	Total	374.87	364	97

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

WESTPORT

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urina	<u>ry</u>		<u>M</u>	elanoma of	<u>Skin</u>				
Male	12.38	9	73	Male	6.38	5	78		
Female	4.12	4	NC*	Female	4.77	1	NC*		
Total	16.50	13	79	Total	11.15	6	54		
Brain and Central Nervous System			<u>M</u>	Multiple Myeloma					
Male	4.19	1	NC*	Male	2.25	4	NC*		
Female	3.67	2	NC*	Female	1.87	3	NC*		
Total	7.86	3	NC*	Total	4.13	7	170		
Breast			Non-Hodgkin's Lymphoma						
Male	0.66	0	NC*	Male	9.12	8	88		

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	68.88	65	94	Female	7.40	5	68	
Total	69.54	65	93	Total	16.52	13	79	
Cervix Uteri			<u>O</u> :	ral Cavity a	nd Pharynx			
				Male	8.61	5	58	
Female	4.29	2	NC*	Female	3.48	3	NC*	
				Total	12.09	8	66	
Colon / Rectum			<u>O</u>	<u>vary</u>				
Male	33.00	33	100					
Female	27.23	24	88	Female	8.33	10	120	
Total	60.23	57	95					
Esophagus			<u>Pa</u>	ancreas				
Male	4.34	10	230 #+	Male	4.63	8	173	
Female	1.36	1	NC*	Female	4.36	2	NC*	
Total	5.70	11	193	Total	8.99	10	111	
Hodgkin's Disease Prostate								
Male	1.80	5	277	Male	75.00	68	91	
Female	1.35	0	NC*					
Total	3.16	5	158					
-	Kidney and Renal Pelvis Stomach							
Male	7.42	7	94	Male	5.41	10	185	
Female	4.04	6	149	Female	2.95	1	NC*	
Total	11.46	13	113	Total	8.36	11	132	
<u>Larynx</u>				<u>estis</u>				
Male	4.72	4	NC*	Male	2.56	3	NC*	
Female	1.21	0	NC*					
Total	5.94	4	NC*					
<u>Leukemia</u>				<u>nyroid</u>				
Male	4.86	7	144	Male	1.18	1	NC*	
Female	3.34	3	NC*	Female	2.95	1	NC*	
Total	8.20	10	122	Total	4.12	2	NC*	
Liver and Intrah	_		· · · · · · · · · · · · · · · · · · ·	teri, Corpus	and Uterus	<u>s, NOS</u>		
Male	2.07	1	NC*		10.14	1.7	100	
Female	0.84	3	NC*	Female	13.14	17	129	
Total	2.91	4	NC*	n Ct. / T				
Lung and Bronch		20		ll Sites / Ty		240	06	
Male	41.77	39	93	Male	249.55	240	96	
Female	26.69	23	86	Female	211.34	183	87	
Total	68.47	62	91	Total	460.90	423	92	

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} <= 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

WESTWOOD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urina	<u>ry</u>		<u>M</u>	<u>lelanoma of</u>	<u>Skin</u>		
Male	11.59	18	155	Male	5.79	12	207 #+
Female	4.26	5	117	Female	4.64	5	108
Total	15.85	23	145	Total	10.43	17	163
Brain and Cen	tral Nervous	System	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>		
Male	3.77	5	133	Male	2.10	2	NC*
Female	3.61	4	NC*	Female	1.93	3	NC*
Total	7.38	9	122	Total	4.03	5	124
Breast			<u>N</u>	on-Hodgkin'	s Lymphom	<u>a</u>	
Male	0.62	0	NC*	Male	8.23	9	109
Female	68.76	76	111	Female	7.51	7	93
Total	69.38	76	110	Total	15.74	16	102
Cervix Uteri			<u>O</u> :	ral Cavity a	nd Pharynx		
				Male	7.95	11	138
Female	4.04	5	124	Female	3.50	4	NC*
				Total	11.44	15	131
Colon / Rectun	<u>n</u>		<u>O</u>	<u>vary</u>			
Male	30.84	38	123				
Female	28.27	31	110	Female	8.23	16	194 #+
Total	59.11	69	117				
Esophagus			<u>Pa</u>	ancreas			
Male	4.05	4	NC*	Male	4.31	4	NC*
Female	1.42	0	NC*	Female	4.52	7	155
Total	5.46	4	NC*	Total	8.83	11	125
Hodgkin's Dis	<u>sease</u>		<u>P</u> 1	<u>rostate</u>			
Male	1.51	2	NC*	Male	70.24	119	169 ^+
Female	1.24	1	NC*				
Total	2.75	3	NC*				
Kidney and Ro	enal Pelvis		<u>St</u>	<u>omach</u>			
Male	6.84	9	132	Male	5.06	5	99

Female	4.09	7	171	Female	3.05	5	164	
Total	10.93	16	146	Total	8.11	10	123	
<u>Larynx</u>			<u>T</u>	<u>estis</u>				
Male	4.40	2	NC*	Male	2.00	5	250	
Female	1.22	0	NC*					
Total	5.62	2	NC*					
<u>Leukemia</u>	<u>Leukemia</u> <u>Thyroid</u>							
Male	4.46	3	NC*	Male	1.01	2	NC*	
Female	3.33	5	150	Female	2.74	4	NC*	
Total	7.79	8	103	Total	3.75	6	160	
Liver and Intr	ahepatic Bile	<u>Ducts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus.	NOS		
Male	1.92	2	NC*					
Female	0.86	2	NC*	Female	13.21	17	129	
Total	2.78	4	NC*					
<u>Lung and Bronchus</u>				All Sites / Types				
Male	38.86	36	93	Male	231.23	298	129 ^+	
Female	27.25	29	106	Female	213.01	250	117 #+	
Total	66.11	65	98	Total	444.24	548	123 ^+	

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

WEYMOUTH

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urina	<u>ry</u>		Melanoma of Skin						
Male	38.60	41	106	Male	20.77	19	91		
Female	16.43	9	55	Female	18.81	17	90		
Total	55.03	50	91	Total	39.57	36	91		
Brain and Central Nervous System			$\underline{\mathbf{M}}$	<u>lultiple Myel</u>					
Male	13.93	13	93	Male	6.99	9	129		

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	14.22	9	63	Female	7.32	8	109
Total	28.14	22	78	Total	14.30	17	119
Breast]	Non-Hodgki	n's Lympho	<u>ma</u>	
Male	2.08	4	NC*	Male	29.84	39	131
Female	263.36	265	101	Female	29.37	26	89
Total	265.44	269	101	Total	59.21	65	110
<u>Cervix Uteri</u>			9	Oral Cavity a	and Pharyn	<u>X</u>	
				Male	27.34	29	106
Female	17.30	22	127	Female	13.37	12	90
				Total	40.71	41	101
Colon / Rectur			-	<u>Ovary</u>			
Male	102.64	127	124 #+				
Female	109.60	127	116	Female	31.95	37	116
Total	212.24	254	120 ~+				
Esophagus			_	<u>Pancreas</u>			
Male	13.48	20	148	Male	14.46	7	48 #-
Female	5.45	6	110	Female	17.26	10	58
Total	18.93	26	137	Total	31.72	17	54 ~-
Hodgkin's Dis			-	Prostate			
Male	6.67	6	90	Male	231.08	279	121 ~+
Female	5.75	7	122				
Total	12.42	13	105				
Kidney and R			-	Stomach_			
Male	23.25	29	125	Male	17.00	13	76
Female	15.47	12	78	Female	12.01	7	58
Total	38.72	41	106	Total	29.01	20	69
<u>Larynx</u>			-	<u>Testis</u>		_	
Male	14.73	25	170 #+	Male	10.15	9	89
Female	4.45	8	180				
Total	19.19	33	172 ~+				
<u>Leukemia</u>	15.70	26	_	Thyroid	4.10	2	MON
Male	15.79	26	165 #+	Male	4.10	2	NC*
Female	13.28	11	83	Female	12.08	13	108
Total	29.08	37	127	Total	16.17	15 NOS	93
Liver and Intr	-		NC*	<u>Uteri, Corpu</u>	<u>is and Uteru</u>	IS, NUS	
Male	6.51	4 3		E1-	40.20	47	06
Female	3.30	3 7	NC*	Female	49.20	47	96
Total Lung and Bro	9.81	1	71	All Sites / Ty	vnoc		
Lung and Broi Male	129.06	160	124 ~+	Male Male	783.94	930	119 ^+
Female	129.06	137	124 ~+	Female	820.73	930 867	119 **+
Total	229.74	297	130 ^+	Total	1604.67	1797	112 ^+
10181	<i>44</i> 7.14	291	149 **+	10181	1004.07	1/7/	114 ~+

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

WHATELY

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urinary	<u>/</u>		<u>M</u>	<u>lelanoma of S</u>	<u>Skin</u>			
Male	1.29	0	NC*	Male	0.64	1	NC*	
Female	0.36	0	NC*	Female	0.45	0	NC*	
Total	1.65	0	NC*	Total	1.09	1	NC*	
Brain and Centr	al Nervous S	<u>System</u>	\mathbf{M}	ultiple Myel	<u>oma</u>			
Male	0.41	0	NC*	Male	0.23	0	NC*	
Female	0.34	0	NC*	Female	0.17	0	NC*	
Total	0.76	0	NC*	Total	0.40	0	NC*	
Breast			No	on-Hodgkin's	<u> Lymphoma</u>	<u>L</u>		
Male	0.07	0	NC*	Male	0.92	0	NC*	
Female	6.33	4	NC*	Female	0.66	2	NC*	
Total	6.39	4	NC*	Total	1.58	2	NC*	
<u>Cervix Uteri</u>			Oral Cavity and Pharynx					
				Male	0.85	0	NC*	
Female	0.41	0	NC*	Female	0.32	0	NC*	
				Total	1.16	0	NC*	
Colon / Rectum			<u>O</u>	<u>vary</u>				
Male	3.42	3	NC*					
Female	2.35	2	NC*	Female	0.77	3	NC*	
Total	5.77	5	87					
Esophagus			<u>Pa</u>	ancreas				
Male	0.43	0	NC*	Male	0.47	1	NC*	
Female	0.12	0	NC*	Female	0.38	0	NC*	
Total	0.55	0	NC*	Total	0.85	1	NC*	
Hodgkin's Disea	ase_		<u>Pr</u>	<u>rostate</u>				

Male	0.18	0	NC*	Male	7.61	6	79
Female	0.13	1	NC*				
Total	0.31	1	NC*				
Kidney and Ren	nal Pelvis		<u>St</u>	<u>omach</u>			
Male	0.74	0	NC*	Male	0.57	2	NC*
Female	0.37	0	NC*	Female	0.25	0	NC*
Total	1.10	0	NC*	Total	0.82	2	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.46	1	NC*	Male	0.25	1	NC*
Female	0.11	0	NC*				
Total	0.58	1	NC*				
Leukemia			<u>T</u>	<u>nyroid</u>			
Male	0.49	0	NC*	Male	0.11	0	NC*
Female	0.30	0	NC*	Female	0.29	0	NC*
Total	0.80	0	NC*	Total	0.40	0	NC*
Liver and Intra	hepatic Bile D	<u>ucts</u>	Uteri, Corpus and Uterus, NOS				
Male	0.21	0	NC*	. =			
Female	0.07	0	NC*	Female	1.21	0	NC*
Total	0.28	0	NC*				
Lung and Brond	chus_		<u>A</u>]	ll Sites / Typ	oes_		
Male	 4.17	1	NC*	Male	25.28	18	71
Female	2.43	0	NC*	Female	19.16	15	78
Total	6.60	1	NC*	Total	44.44	33	74
2 0 0001	0.00	*	2,0	2 0 0002			

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

WHITMAN

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

Exp Obs SIR Exp Obs SIR

Bladder, Urinary Melanoma of Skin

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	7.99	7	88	Male	4.44	1	NC*
Female	2.70	0	NC*	Female	3.53	8	227
Total	10.69	7	65	Total	7.97	9	113
Brain and Cent	tral Nervous S	<u>System</u>	<u>M</u>	ultiple Mye	<u>loma</u>		
Male	3.12	2	NC*	Male	1.46	1	NC*
Female	2.70	1	NC*	Female	1.22	0	NC*
Total	5.82	3	NC*	Total	2.68	1	NC*
Breast			<u>N</u>	on-Hodgkin	's Lymphoma	<u>1</u>	
Male	0.44	1	NC*	Male	6.41	4	NC*
Female	47.04	51	108	Female	5.07	6	118
Total	47.48	52	110	Total	11.49	10	87
Cervix Uteri			<u>O</u> :	ral Cavity a	nd Pharynx		
				Male	5.82	3	NC*
Female	3.40	2	NC*	Female	2.35	2	NC*
				Total	8.17	5	61
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>			
Male	21.27	27	127				
Female	17.83	18	101	Female	5.86	7	119
Total	39.10	45	115				
Esophagus			<u>Pa</u>	ancreas			
Male	2.84	4	NC*	Male	3.01	4	NC*
Female	0.88	3	NC*	Female	2.83	4	NC*
Total	3.72	7	188	Total	5.84	8	137
Hodgkin's Disc	ease		<u>P1</u>	<u>rostate</u>			
Male	1.55	4	NC*	Male	47.43	36	76
Female	1.22	0	NC*				
Total	2.77	4	NC*				
Kidney and Re	nal Pelvis		<u>St</u>	<u>omach</u>			
Male	4.96	7	141	Male	3.53	3	NC*
Female	2.71	5	184	Female	1.96	5	255
Total	7.67	12	156	Total	5.48	8	146
<u>Larynx</u>				<u>estis</u>			
Male	3.10	1	NC*	Male	2.31	0	NC*
Female	0.79	0	NC*				
Total	3.89	1	NC*				
<u>Leukemia</u>			<u>Tl</u>	<u>nyroid</u>			
Male	3.51	4	NC*	Male	0.91	2	NC*
Female	2.48	3	NC*	Female	2.45	1	NC*
Total	5.99	7	117	Total	3.36	3	NC*
Liver and Intra	<u>thepatic Bile I</u>	<u>Ducts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	1.38	0	NC*				
Female	0.56	0	NC*	Female	8.68	6	69
Total	1.94	0	NC*				
Lung and Bron	<u>chus</u>		<u>A</u> l	ll Sites / Typ	<u>pes</u>		

Male	27.00	26	96	Male	164.40	151	92
Female	17.22	23	134	Female	143.86	153	106
Total	44.22	49	111	Total	308.26	304	99

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

WILBRAHAM

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR	
Bladder, Urina	<u>ry</u>		$\underline{\mathbf{M}}$	elanoma of	<u>Skin</u>			
Male	11.81	16	136	Male	5.87	10	170	
Female	4.10	2	NC*	Female	4.54	8	176	
Total	15.90	18	113	Total	10.40	18	173 #+	
Brain and Cent	tral Nervous S	<u>System</u>	<u>M</u>	<u>ultiple Mye</u>	<u>loma</u>			
Male	3.81	4	NC*	Male	2.14	2	NC*	
Female	3.54	5	141	Female	1.85	3	NC*	
Total	7.35	9	122	Total	3.99	5	125	
Breast		Non-Hodgkin's Lymphoma						
Male	0.63	0	NC*	Male	8.30	9	108	
Female	66.83	80	120	Female	7.25	9	124	
Total	67.46	80	119	Total	15.55	18	116	
Cervix Uteri			<u>O</u> :	ral Cavity a	nd Pharynx			
				Male	8.12	2	NC*	
Female	3.98	4	NC*	Female	3.40	2	NC*	
				Total	11.52	4	NC*	
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>				
Male	31.38	28	89					
Female	27.14	33	122	Female	8.02	9	112	
Total	58.52	61	104					
Esophagus			<u>Pa</u>	ancreas				

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	4.14	3	NC*	Male	4.39	2	NC*		
Female	1.36	1	NC*	Female	4.33	5	115		
Total	5.50	4	NC*	Total	8.72	7	80		
Hodgkin's Di	<u>sease</u>		<u>Pr</u>	<u>costate</u>					
Male	1.48	1	NC*	Male	71.50	77	108		
Female	1.23	0	NC*						
Total	2.71	1	NC*						
Kidney and Renal Pelvis Stomach									
Male	6.96	7	101	Male	5.15	2	NC*		
Female	3.96	4	NC*	Female	2.94	4	NC*		
Total	10.92	11	101	Total	8.09	6	74		
<u>Larynx</u>			<u>Testis</u>						
Male	4.51	2	NC*	Male	1.89	2	NC*		
Female	1.18	1	NC*						
Total	5.69	3	NC*						
<u>Leukemia</u>			<u>T</u>	<u>nyroid</u>					
Male	4.53	4	NC*	Male	1.00	2	NC*		
Female	3.26	2	NC*	Female	2.71	4	NC*		
Total	7.79	6	77	Total	3.71	6	162		
Liver and Int	rahepatic Bile	Ducts	<u>U1</u>	t <mark>eri, Corpus</mark>	s and Uterus	, NOS			
Male	1.95	1	NC*						
Female	0.83	1	NC*	Female	12.82	15	117		
Total	2.78	2	NC*						
Lung and Bro	onchus_		<u>A</u> l	ll Sites / Ty	pes				
Male	39.60	40	101	Male	235.05	225	96		
Female	26.18	21	80	Female	206.31	227	110		
Total	65.79	61	93	Total	441.35	452	102		

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

WILLIAMSBURG

Cancer Incidence by Sex, 1990 - 1995

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	SIR	
Bladder, Urina	<u>ry</u>		<u>M</u>	lelanoma of	<u>Skin</u>			
Male	1.83	3	NC*	Male	0.99	1	NC*	
Female	0.70	1	NC*	Female	0.82	1	NC*	
Total	2.53	4	NC*	Total	1.81	2	NC*	
Brain and Cent	tral Nervous S	<u>System</u>	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>			
Male	0.67	1	NC*	Male	0.33	0	NC*	
Female	0.62	1	NC*	Female	0.31	1	NC*	
Total	1.29	2	NC*	Total	0.64	1	NC*	
Breast			No	<u>on-Hodgkin'</u>	s Lymphoma	<u>1</u>		
Male	0.10	0	NC*	Male	1.42	2	NC*	
Female	11.30	19	168 #+	Female	1.27	1	NC*	
Total	11.40	19	167 #+	Total	2.68	3	NC*	
<u>Cervix Uteri</u>			Oral Cavity and Pharynx					
				Male	1.31	1	NC*	
Female	0.77	0	NC*	Female	0.57	1	NC*	
				Total	1.87	2	NC*	
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>				
Male	4.87	7	144					
Female	4.70	2	NC*	Female	1.38	1	NC*	
Total	9.57	9	94					
Esophagus			<u>Pa</u>	ancreas				
Male	0.64	1	NC*	Male	0.69	0	NC*	
Female	0.23	0	NC*	Female	0.73	0	NC*	
Total	0.88	1	NC*	Total	1.42	0	NC*	
Hodgkin's Disc	<u>ease</u>		<u>P</u> 1	<u>rostate</u>				
Male	0.32	1	NC*	Male	11.05	4	NC*	
Female	0.27	0	NC*					
Total	0.58	1	NC*					
Kidney and Re	<u>enal Pelvis</u>		<u>St</u>	<u>comach</u>				
Male	1.12	1	NC*	Male	0.80	0	NC*	
Female	0.66	1	NC*	Female	0.52	0	NC*	
Total	1.78	2	NC*	Total	1.32	0	NC*	
<u>Larynx</u>			<u>T</u>	<u>estis</u>				
Male	0.71	0	NC*	Male	0.47	0	NC*	
Female	0.19	0	NC*					
Total	0.89	0	NC*					
Leukemia				<u>hyroid</u>				
Male	0.75	0	NC*	Male	0.19	0	NC*	
Female	0.59	2	NC*	Female	0.55	0	NC*	
Total	1.34	2	NC*	Total	0.74	0	NC*	

<u>Liver and Intrahepatic Bile Ducts</u>			<u>Uteri, Corpus and Uterus, NOS</u>				
0.31	1	NC*					
0.14	0	NC*	Female	2.08	3	NC*	
0.45	1	NC*					
Lung and Bronchus			All Sites / Types				
6.20	9	145	Male	37.39	35	94	
4.23	6	142	Female	35.22	42	119	
10.43	15	144	Total	72.61	77	106	
	0.31 0.14 0.45 chus 6.20 4.23	0.31 1 0.14 0 0.45 1 chus 6.20 9 4.23 6	0.31 1 NC* 0.14 0 NC* 0.45 1 NC* chus All 6.20 9 145 4.23 6 142	0.31 1 NC* 0.14 0 NC* Female 0.45 1 NC* chus All Sites / Tyr 6.20 9 145 Male 4.23 6 142 Female	0.31 1 NC* 0.14 0 NC* Female 2.08 0.45 1 NC* All Sites / Types 6.20 9 145 Male 37.39 4.23 6 142 Female 35.22	0.31 1 NC* 0.14 0 NC* Female 2.08 3 0.45 1 NC* Chus All Sites / Types 6.20 9 145 Male 37.39 35 4.23 6 142 Female 35.22 42	

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

WILLIAMSTOWN

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinar	<u>v</u>		<u>M</u>	elanoma of	<u>Skin</u>		
Male	6.62	6	91	Male	3.25	5	154
Female	3.34	1	NC*	Female	3.08	4	NC*
Total	9.96	7	70	Total	6.33	9	142
Brain and Cent	ral Nervous S	<u>System</u>	<u>M</u>	ultiple Mye	<u>loma</u>		
Male	2.15	1	NC*	Male	1.18	0	NC*
Female	2.37	3	NC*	Female	1.42	0	NC*
Total	4.53	4	NC*	Total	2.60	0	NC*
Breast			<u>N</u>	on-Hodgkin'	s Lymphoma	<u>a</u>	
Male	0.34	0	NC*	Male	4.75	3	NC*
Female	44.94	42	93	Female	5.54	4	NC*
Total	45.28	42	93	Total	10.30	7	68
Cervix Uteri			<u>O</u> 1	ral Cavity ar	nd Pharynx		
				Male	4.17	2	NC*
Female	2.59	0	NC*	Female	2.37	1	NC*
				Total	6.54	3	NC*

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Colon / Rectum	<u>ı</u>		<u>O</u>	<u>vary</u>			
Male	17.49	11	63				
Female	22.90	14	61	Female	5.28	3	NC*
Total	40.38	25	62 #-				
Esophagus			<u>Pa</u>	ncreas			
Male	2.15	1	NC*	Male	2.36	1	NC*
Female	1.13	3	NC*	Female	3.45	5	145
Total	3.27	4	NC*	Total	5.81	6	103
Hodgkin's Disc	<u>ease</u>		<u>Pr</u>	<u>ostate</u>			
Male	1.00	1	NC*	Male	38.81	43	111
Female	0.85	0	NC*				
Total	1.85	1	NC*				
Kidney and Re	enal Pelvis		<u>St</u>	<u>omach</u>			
Male	3.65	2	NC*	Male	2.91	0	NC*
Female	2.74	4	NC*	Female	2.58	4	NC*
Total	6.39	6	94	Total	5.49	4	NC*
<u>Larynx</u>			<u>Te</u>	<u>estis</u>			
Male	2.28	4	NC*	Male	1.45	0	NC*
Female	0.72	0	NC*				
Total	3.00	4	NC*				
Leukemia			<u>Tl</u>	<u>iyroid</u>			
Male	2.60	3	NC*	Male	0.60	0	NC*
Female	2.48	4	NC*	Female	1.78	2	NC*
Total	5.08	7	138	Total	2.38	2	NC*
Liver and Intra	ahepatic Bile	<u>Ducts</u>	<u>U1</u>	t <mark>eri, Corpus</mark>	and Uterus,	NOS	
Male	1.04	0	NC*				
Female	0.63	0	NC*	Female	8.24	8	97
Total	1.68	0	NC*				
Lung and Bron	chus		<u>A</u> l	l Sites / Ty	<u>pes</u>		
Male	20.71	19	92	Male	128.59	109	85
Female	17.32	13	75	Female	147.53	122	83 #-
Total	38.03	32	84	Total	276.12	231	84 ~-

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

WILMINGTON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urina	<u>ry</u>			elanoma of	<u>Skin</u>		
Male	10.97	8	73	Male	6.42	5	78
Female	3.72	6	161	Female	5.15	9	175
Total	14.68	14	95	Total	11.57	14	121
Brain and Cent	<u>ral Nervous S</u>	<u>System</u>	<u>M</u>	<u>ultiple Mye</u>	<u>loma</u>		
Male	4.50	1	NC*	Male	2.02	2	NC*
Female	3.90	7	180	Female	1.71	3	NC*
Total	8.40	8	95	Total	3.73	5	134
Breast			<u>Ne</u>	on-Hodgkin'	s Lymphoma	<u>a</u>	
Male	0.61	0	NC*	Male	9.10	13	143
Female	69.40	76	110	Female	7.12	7	98
Total	70.01	76	109	Total	16.22	20	123
<u>Cervix Uteri</u>			\mathbf{O}	<u>ral Cavity an</u>	nd Pharynx		
				Male	8.65	11	127
Female	4.97	6	121	Female	3.43	4	NC*
				Total	12.08	15	124
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>			
Male	29.26	32	109				
Female	24.10	27	112	Female	8.66	7	81
Total	53.36	59	111				
Esophagus			<u>Pa</u>	ncreas			
Male	4.11	0	NC*	Male	4.27	4	NC*
Female	1.20	0	NC*	Female	3.92	6	153
Total	5.31	0	NC*	Total	8.19	10	122
Hodgkin's Disc	<u>ease</u>		<u>Pr</u>	ostate			
Male	2.20	6	273	Male	65.47	64	98
Female	1.71	4	NC*				
Total	3.91	10	256 #+				
Kidney and Re	nal Pelvis		<u>St</u>	<u>omach</u>			
Male	7.18	10	139	Male	4.86	5	103
Female	3.93	5	127	Female	2.61	3	NC*
Total	11.11	15	135	Total	7.47	8	107
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	4.58	3	NC*	Male	3.31	4	NC*
Female	1.21	2	NC*				

Total	5.79	5	86				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	4.91	8	163	Male	1.33	0	NC*
Female	3.42	6	176	Female	3.54	5	141
Total	8.33	14	168	Total	4.87	5	103
Liver and Int	rahepatic Bile	ic Bile Ducts <u>Uteri, Corpus and Uterus, NOS</u>					
Male	1.97	2	NC*				
Female	0.79	0	NC*	Female	13.03	21	161
Total	2.76	2	NC*				
Lung and Bro	nchus_		<u>A</u>	ll Sites / Ty	<u>pes</u>		
Male	38.56	53	137 #+	Male	231.00	251	109
Female	25.50	30	118	Female	207.33	249	120 ~+
Total	64.06	83	130 #+	Total	438.33	500	114 ~+

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases

WINCHENDON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	$\mathbf{\underline{Exp}}$	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urina	<u>ry</u>	Melanoma of Skin							
Male	5.68	6	106	Male	3.12	2	NC*		
Female	2.19	2	NC*	Female	2.62	2	NC*		
Total	7.87	8	102	Total	5.74	4	NC*		
Brain and Cen	tral Nervous	System	<u>M</u>	ultiple Mye	<u>loma</u>				
Male	2.20	1	NC*	Male	1.03	2	NC*		
Female	2.02	2	NC*	Female	0.97	0	NC*		
Total	4.22	3	NC*	Total	2.00	2	NC*		
Breast			Non-Hodgkin's Lymphoma						
Male	0.31	0	NC*	Male	4.54	3	NC*		
Female	35.36	24	68	Female	3.99	2	NC*		

^{* =} SIR and statistical significance not calculated when Obs < 5

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Total	35.67	24	67	Total	8.52	5	59
Cervix Uteri			<u>O</u> :	ral Cavity a	nd Pharynx		
				Male	4.04	4	NC*
Female	2.48	7	283 #+	Female	1.79	8	446 ~+
				Total	5.84	12	206 #+
Colon / Rectum	_		<u>O</u>	<u>vary</u>			
Male	15.11	9	60				
Female	14.64	15	102	Female	4.36	6	138
Total	29.75	24	81				
Esophagus			<u>Pa</u>	<u>ancreas</u>			
Male	1.98	4	NC*	Male	2.12	1	NC*
Female	0.72	0	NC*	Female	2.28	0	NC*
Total	2.70	4	NC*	Total	4.41	1	NC*
Hodgkin's Dise	<u>ease</u>		<u>Pı</u>	<u>rostate</u>			
Male	1.11	1	NC*	Male	33.67	22	65 #-
Female	0.90	0	NC*				
Total	2.00	1	NC*				
Kidney and Re	<u>nal Pelvis</u>		St	<u>omach</u>			
Male	3.47	5	144	Male	2.51	2	NC*
Female	2.08	6	289 #+	Female	1.62	2	NC*
Total	5.54	11	198	Total	4.13	4	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	2.16	4	NC*	Male	1.66	0	NC*
Female	0.58	1	NC*				
Total	2.74	5	183				
<u>Leukemia</u>			<u>Tl</u>	<u>nyroid</u>			
Male	2.50	1	NC*	Male	0.64	0	NC*
Female	1.92	2	NC*	Female	1.78	0	NC*
Total	4.42	3	NC*	Total	2.42	0	NC*
Liver and Intra	hepatic Bile	<u>Ducts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus	NOS	
Male	0.97	1	NC*				
Female	0.45	0	NC*	Female	6.48	7	108
Total	1.42	1	NC*				
Lung and Bron	<u>chus</u>		<u>A</u>]	ll Sites / Ty			
Male	18.92	18	95	Male	116.22	87	75 ~-
Female	13.12	7	53	Female	110.58	101	91
Total	32.05	25	78	Total	226.79	188	83 ~-

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

WINCHESTER

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		
Bladder, Urina	<u>ry</u>		\mathbf{M}	<u>lelanoma of</u>	Skin				
Male	17.34	13	75	Male	8.67	12	138		
Female	6.69	4	NC*	Female	7.12	15	211 #+		
Total	24.04	17	71	Total	15.79	27	171 #+		
Brain and Cent	tral Nervous	<u>System</u>	<u>M</u>	<u>lultiple Mye</u>	<u>eloma</u>				
Male	5.61	6	107	Male	3.13	4	NC*		
Female	5.46	7	128	Female	2.97	5	168		
Total	11.07	13	117	Total	6.10	9	148		
Breast			Non-Hodgkin's Lymphoma						
Male	0.92	0	NC*	Male	12.33	13	105		
Female	103.55	110	106	Female	11.65	15	129		
Total	104.47	110	105	Total	23.98	28	117		
Cervix Uteri			<u>O</u> :	ral Cavity a	<u>nd Pharynx</u>				
				Male	11.76	13	111		
Female	6.23	4	NC*	Female	5.30	7	132		
				Total	17.06	20	117		
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>					
Male	45.99	48	104						
Female	44.89	55	123	Female	12.39	14	113		
Total	90.88	103	113						
Esophagus			<u>Pa</u>	ancreas					
Male	5.98	5	84	Male	6.37	6	94		
Female	2.23	2	NC*	Female	7.02	7	100		
Total	8.21	7	85	Total	13.39	13	97		
Hodgkin's Dis	<u>ease</u>		<u>P</u> 1	<u>rostate</u>					
Male	2.31	0	NC*	Male	103.03	117	114		
Female	1.97	4	NC*						
Total	4.28	4	NC*						
Kidney and Re	enal Pelvis		<u>St</u>	omach_					
Male	10.07	16	159	Male	7.60	6	79		
Female	6.13	5	82	Female	4.94	3	NC*		

Total	16.20	21	130	Total	12.54	9	72
Larynx			,	<u>Testis</u>			
Male	6.47	5	77	Male	3.13	7	224
Female	1.77	3	NC*				
Total	8.23	8	97				
Leukemia			, -	<u>Thyroid</u>			
Male	6.66	5	75	Male	1.52	3	NC*
Female	5.23	5	96	Female	4.27	6	140
Total	11.89	10	84	Total	5.80	9	155
<u>Liver and Intrahepatic Bile Ducts</u> <u>U</u>				<u>Uteri, Corpu</u>	s and Uter	us, NOS	
Male	2.83	5	176				
Female	1.32	0	NC*	Female	19.50	20	103
Total	4.15	5	120				
Lung and Bro	onchus_		4	All Sites / Ty	vpes		
Male	56.98	41	72 #-	Male	342.22	338	99
Female	39.93	36	90	Female	324.69	352	108
Total	96.91	77	79 #-	Total	666.91	690	103

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

WINDSOR

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	SIR				
Bladder, Urina	<u>ry</u>	Melanoma of Skin									
Male	0.60	0	NC*	Male	0.31	0	NC*				
Female	0.14	0	NC*	Female	0.21	0	NC*				
Total	0.75	0	NC*	Total	0.52	0	NC*				
Brain and Cen	d Central Nervous System Multiple Myel										
Male	0.21	0	NC*	Male	0.11	1	NC*				
Female	0.16	0	NC*	Female	0.07	0	NC*				

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Total	0.37	0	NC*	Total	0.17	1	NC*
Breast			<u>N</u> e	on-Hodgkin'	s Lymphoma	<u>ı</u>	
Male	0.03	0	NC*	Male	0.45	0	NC*
Female	2.74	4	NC*	Female	0.28	0	NC*
Total	2.78	4	NC*	Total	0.73	0	NC*
Cervix Uteri			<u>O</u> :	ral Cavity ar	nd Pharynx		
				Male	0.42	0	NC*
Female	0.20	0	NC*	Female	0.14	0	NC*
				Total	0.55	0	NC*
Colon / Rectum	<u>L</u>		\mathbf{O}	<u>vary</u>			
Male	1.59	0	NC*				
Female	0.92	1	NC*	Female	0.35	0	NC*
Total	2.51	1	NC*				
Esophagus			<u>Pa</u>	ancreas			
Male	0.21	0	NC*	Male	0.22	0	NC*
Female	0.05	0	NC*	Female	0.15	0	NC*
Total	0.25	0	NC*	Total	0.37	0	NC*
Hodgkin's Dise	<u>ease</u>			<u>rostate</u>			
Male	0.10	0	NC*	Male	3.52	2	NC*
Female	0.07	0	NC*				
Total	0.17	0	NC*				
Kidney and Re	<u>nal Pelvis</u>			<u>omach</u>			
Male	0.35	0	NC*	Male	0.27	0	NC*
Female	0.16	0	NC*	Female	0.10	0	NC*
Total	0.51	0	NC*	Total	0.37	0	NC*
<u>Larynx</u>				<u>estis</u>			
Male	0.22	0	NC*	Male	0.14	0	NC*
Female	0.05	0	NC*				
Total	0.27	0	NC*				
<u>Leukemia</u>				<u>nyroid</u>			
Male	0.25	0	NC*	Male	0.06	0	NC*
Female	0.14	1	NC*	Female	0.15	0	NC*
Total	0.39	1	NC*	Total	0.21	0	NC*
Liver and Intra				<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	0.10	0	NC*				
Female	0.03	0	NC*	Female	0.52	1	NC*
Total	0.13	0	NC*	n at			
Lung and Bron		0		ll Sites / Tyr		2	Mark
Male	1.96	0	NC*	Male	11.97	3	NC*
Female	1.01	0	NC*	Female	8.19	8	98
Total	2.97	0	NC*	Total	20.15	11	55 #-

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

WINTHROP

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urina	<u>ry</u>		<u>M</u>	<u>lelanoma of</u>	<u>Skin</u>				
Male	14.81	14	95	Male	7.49	14	187 #+		
Female	6.82	1	NC*	Female	6.96	10	144		
Total	21.64	15	69	Total	14.45	24	166 #+		
Brain and Cent	tral Nervous	<u>System</u>	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>				
Male	4.85	3	NC*	Male	2.66	1	NC*		
Female	5.25	6	114	Female	2.98	4	NC*		
Total	10.10	9	89	Total	5.64	5	89		
Breast			Non-Hodgkin's Lymphoma						
Male	0.78	3	NC*	Male	10.81	14	130		
Female	100.34	87	87	Female	11.72	16	136		
Total	101.12	90	89	Total	22.53	30	133		
<u>Cervix Uteri</u>			Oral Cavity and Pharynx						
				Male	9.80	16	163		
Female	6.12	4	NC*	Female	5.17	4	NC*		
				Total	14.97	20	134		
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>					
Male	39.25	40	102						
Female	46.27	48	104	Female	11.94	13	109		
Total	85.52	88	103						
Esophagus			<u>Pa</u>	ancreas					
Male	4.98	1	NC*	Male	5.39	7	130		
Female	2.28	1	NC*	Female	7.14	11	154		
Total	7.26	2	NC*	Total	12.53	18	144		
Hodgkin's Disc	<u>ease</u>		<u>P</u> 1	<u>rostate</u>					
Male	2.21	3	NC*	Male	87.69	86	98		

Female	1.96	1	NC*						
Total	4.17	4	NC*						
Kidney and Re	nal Pelvis		<u>St</u>	Stomach_					
Male	8.45	8	95	Male	6.51	5	77		
Female	5.99	6	100	Female	5.13	5	98		
Total	14.44	14	97	Total	11.64	10	86		
<u>Larynx</u>			<u>Testis</u>						
Male	5.34	9	168	Male	3.29	4	NC*		
Female	1.66	2	NC*						
Total	7.00	11	157						
Leukemia			<u>T</u>	<u>hyroid</u>					
Male	5.70	0	NC*	Male	1.39	0	NC*		
Female	5.16	5	97	Female	4.21	8	190		
Total	10.86	5	46	Total	5.60	8	143		
Liver and Intra	hepatic Bile	<u>Ducts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus	, NOS			
Male	2.39	4	NC*						
Female	1.33	2	NC*	Female	18.63	12	64		
Total	3.72	6	161						
Lung and Bron	<u>chus</u>		<u>A</u>	ll Sites / Ty	<u>pes</u>				
Male	47.79	54	113	Male	291.97	314	108		
Female	38.82	60	155 ~+	Female	320.19	327	102		
Total	86.61	114	132 ~+	Total	612.16	641	105		

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

WOBURN

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	\mathbf{Exp}	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinar	<u>v</u>		<u>M</u>	elanoma of S	<u>Skin</u>		
Male	25.51	26	102	Male	13.87	15	108

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the p <= 0.01 level, as well as at the p <= 0.05 level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	10.08	7	69	Female	11.98	26	217 ^+
Total	35.60	33	93	Total	25.85	41	159 ~+
Brain and Cen	tral Nervous	<u>System</u>	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>		
Male	9.37	4	NC*	Male	4.62	0	NC*
Female	9.07	13	143	Female	4.54	12	265 ~+
Total	18.44	17	92	Total	9.15	12	131
Breast				s Lymphoma	<u>1</u>		
Male	1.38	1	NC*	Male	19.95	18	90
Female	167.42	166	99	Female	18.27	25	137
Total	168.80	167	99	Total	38.22	43	113
<u>Cervix Uteri</u>			<u>O</u>	<u>ral Cavity aı</u>	<u>nd Pharynx</u>		
				Male	18.23	14	77
Female	11.12	6	54	Female	8.46	8	95
				Total	26.68	22	82
Colon / Rectum				<u>vary</u>			
Male	67.92	82	121				
Female	66.76	83	124	Female	20.40	20	98
Total	134.68	165	123 #+				
Esophagus				ancreas			
Male	8.95	11	123	Male	9.62	8	83
Female	3.33	3	NC*	Female	10.62	16	151
Total	12.28	14	114	Total	20.24	24	119
Hodgkin's Disc				<u>rostate</u>			
Male	4.55	8	176	Male	153.92	172	112
Female	3.68	11	299 ~+				
Total	8.23	19	231 ~+	_			
Kidney and Re		22		omach	11.01	0	
Male	15.50	22	142	Male	11.24	8	71
Female	9.77	14	143	Female	7.27	9	124
Total	25.27	36	142	Total	18.51	17	92
<u>Larynx</u>	0.02	10		estis_	6.00	0	100
Male	9.82	12	122	Male	6.99	9	129
Female	2.87	6	209				
Total	12.69	18	142				
<u>Leukemia</u> Male	10.56	9	85	<u>hyroid</u> Male	2.79	4	NC*
Female	10.56 8.30	9	108	Female	2.78 7.76		
remaie Total	8.30 18.86	18	108 95	Total		10 14	129
					10.54		133
Liver and Intra Male	4.34	<u>Ducis</u> 3	NC*	ieri, Corpus	and Uterus,	HUS	
Female	2.05	3 4	NC*	Female	31.46	27	86
Total	6.39	7	110	1 Ciliaic	J1. 4 0	21	00
Lung and Bron		,		ll Sites / Ty	nes		
Male	85.94	89	104	Male	522.01	552	106
1viuic	55.54		107	1,1010	22.01	554	100

Female	63.91	76	119	Female	516.29	602	117 ^+
Total	149.85	165	110	Total	1038.29	1154	111 ^+

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

WORCESTER

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR		
Bladder, Urina	<u>ry</u>		<u>M</u>	elanoma of	<u>Skin</u>				
Male	126.35	116	92	Male	63.64	60	94		
Female	53.29	62	116	Female	56.54	41	73 #-		
Total	179.64	178	99	Total	120.18	101	84		
Brain and Cen	tral Nervous	<u>System</u>	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>				
Male	42.88	31	72	Male	22.61	18	80		
Female	43.70	37	85	Female	23.37	18	77		
Total	86.58	68	79 #-	Total	45.98	36	78		
Breast			Non-Hodgkin's Lymphoma						
Male	6.61	8	121	Male	93.78	103	110		
Female	795.97	720	90 ~-	Female	93.30	103	110		
Total	802.59	728	91 ~-	Total	187.08	206	110		
Cervix Uteri			<u>O</u> :	ral Cavity a	nd Pharynx				
				Male	80.66	84	104		
Female	50.90	64	126	Female	40.92	36	88		
				Total	121.59	120	99		
Colon / Rectun	<u>n_</u>		<u>O</u>	<u>vary</u>					
Male	334.66	301	90						
Female	360.92	339	94	Female	95.90	100	104		
Total	695.59	640	92 #-						
Esophagus			<u>Pa</u>	ancreas					
Male	41.21	45	109	Male	45.40	35	77		

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	17.82	16	90	Female	55.95	41	73 #-
Total	59.03	61	103	Total	101.35	76	75 #-
Hodgkin's Dis	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Male	20.95	17	81	Male	745.67	648	87 ^-
Female	17.68	19	107				
Total	38.63	36	93				
Kidney and Ro	enal Pelvis		<u>St</u>	<u>omach</u>			
Male	71.01	74	104	Male	55.51	52	94
Female	47.99	35	73	Female	39.86	41	103
Total	119.00	109	92	Total	95.37	93	98
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	43.77	45	103	Male	31.44	29	92
Female	13.03	16	123				
Total	56.81	61	107				
<u>Leukemia</u>			<u>T</u>	<u>hyroid</u>			
Male	50.75	46	91	Male	12.31	11	89
Female	42.88	31	72	Female	35.82	29	81
Total	93.63	77	82	Total	48.13	40	83
Liver and Intr	ahepatic Bil	e Ducts	<u>U</u> 1	teri, Corpus	s and Uterus,	NOS	
Male	20.22	24	119				
Female	10.61	4	NC*	Female	147.10	165	112
Total	30.83	28	91				
Lung and Bron	<u>Lung and Bronchus</u> <u>All Sites / Types</u>						
Male	400.11	388	97	Male	2487.32	2301	93 ^-
Female	307.97	323	105	Female	2544.89	2409	95 ~-
Total	708.08	711	100	Total	5032.21	4710	94 ^-

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

WORTHINGTON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>			
Bladder, Urinary	_		$\underline{\mathbf{M}}$	<u>lelanoma of S</u>	<u>Skin</u>					
Male	0.79	0	NC*	Male	0.45	1	NC*			
Female	0.23	0	NC*	Female	0.32	0	NC*			
Total	1.02	0	NC*	Total	0.77	1	NC*			
Brain and Centra	<u>al Nervous</u>	<u>System</u>	$\underline{\mathbf{M}}$	Multiple Myeloma						
Male	0.31	1	NC*	Male	0.14	0	NC*			
Female	0.24	0	NC*	Female	0.11	0	NC*			
Total	0.56	1	NC*	Total	0.25	0	NC*			
<u>Breast</u>			<u>N</u>	on-Hodgkin's	s Lymphoma	<u>l</u>				
Male	0.04	0	NC*	Male	0.64	0	NC*			
Female	4.30	3	NC*	Female	0.45	0	NC*			
Total	4.34	3	NC*	Total	1.08	0	NC*			
<u>Cervix Uteri</u>			<u>O</u> :	ral Cavity an	d Pharynx					
				Male	0.60	0	NC*			
Female	0.31	0	NC*	Female	0.21	0	NC*			
				Total	0.82	0	NC*			
Colon / Rectum			<u>O</u>							
Male	2.10	3	NC*							
Female	1.52	2	NC*	Female	0.54	1	NC*			
Total	3.62	5	138							
Esophagus			<u>Pa</u>	ancreas_						
Male	0.29	0	NC*	Male	0.30	0	NC*			
Female	0.07	0	NC*	Female	0.24	1	NC*			
Total	0.37	0	NC*	Total	0.55	1	NC*			
Hodgkin's Disea	<u>se</u>		<u>P</u> 1	<u>rostate</u>						
Male	0.15	2	NC*	Male	4.71	2	NC*			
Female	0.11	0	NC*							
Total	0.26	2	NC*							
Kidney and Rena	ıl Pelvis		<u>St</u>	<u>omach</u>						
Male	0.51	0	NC*	Male	0.35	0	NC*			
Female	0.24	1	NC*	Female	0.17	0	NC*			
Total	0.75	1	NC*	Total	0.51	0	NC*			
<u>Larynx</u>			<u>T</u>	<u>estis</u>						
Male	0.32	0	NC*	Male	0.22	0	NC*			
Female	0.07	0	NC*							
Total	0.40	0	NC*							
<u>Leukemia</u>			<u>T</u>	<u>nyroid</u>						
Male	0.34	0	NC*	Male	0.09	1	NC*			
Female	0.22	0	NC*	Female	0.22	0	NC*			
Total	0.56	0	NC*	Total	0.31	1	NC*			
Liver and Intrah	<u>epatic Bile</u>	<u>Ducts</u>	<u>Uteri, Corpus and Uterus, NOS</u>							
Male	0.14	0	NC*							

Female	0.05	0	NC*	Female	0.80	0	NC*
Total	0.19	0	NC*				
Lung and Broi	<u>nchus</u>		<u>A</u>]	ll Sites / Typ	<u>oes</u>		
Male	2.74	2	NC*	Male	16.41	13	79
Female	1.55	0	NC*	Female	12.89	9	70
Total	4.29	2	NC*	Total	29.30	22	75

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

WRENTHAM

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urinaı	<u>v</u>		<u>M</u>	elanoma of	<u>Skin</u>			
Male	6.15	9	146	Male	3.48	3	NC*	
Female	2.42	3	NC*	Female	2.88	6	209	
Total	8.58	12	140	Total	6.36	9	141	
Brain and Cent	ral Nervous S	<u>System</u>	Multiple Myeloma					
Male	2.38	3	NC*	Male	1.12	1	NC*	
Female	2.17	1	NC*	Female	1.07	1	NC*	
Total	4.55	4	NC*	Total	2.19	2	NC*	
Breast			Non-Hodgkin's Lymphoma					
Male	0.34	1	NC*	Male	4.94	4	NC*	
Female	39.25	45	115	Female	4.36	3	NC*	
Total	39.59	46	116	Total	9.30	7	75	
Cervix Uteri			<u>O</u> 1	ral Cavity ar	nd Pharynx			
				Male	4.59	4	NC*	
Female	2.67	1	NC*	Female	1.99	1	NC*	
				Total	6.58	5	76	
Colon / Rectum	<u>_</u>	<u>Ovary</u>						
Male	16.24	13	80					

^{* =} SIR and statistical significance not calculated when Obs < 5

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	16.16	14	87	Female	4.81	4	NC*		
Total	32.40	27	83						
Esophagus			<u>Pa</u>	<u>ancreas</u>					
Male	2.20	3	NC*	Male	2.29	1	NC*		
Female	0.80	0	NC*	Female	2.51	4	NC*		
Total	3.00	3	NC*	Total	4.79	5	104		
Hodgkin's Disc	ease_		<u>P1</u>	<u>rostate</u>					
Male	1.17	0	NC*	Male	34.40	29	84		
Female	0.92	0	NC*						
Total	2.09	0	NC*						
Kidney and Re	nal Pelvis		<u>St</u>	<u>omach</u>					
Male	3.78	2	NC*	Male	2.75	2	NC*		
Female	2.26	2	NC*	Female	1.80	0	NC*		
Total	6.04	4	NC*	Total	4.56	2	NC*		
<u>Larynx</u>	<u>Testis</u>								
Male	2.40	5	209	Male	1.78	2	NC*		
Female	0.65	1	NC*						
Total	3.05	6	197						
Leukemia			<u>Tl</u>	Thyroid					
Male	2.65	3	NC*	Male	0.71	0	NC*		
Female	2.06	1	NC*	Female	1.90	3	NC*		
Total	4.71	4	NC*	Total	2.60	3	NC*		
Liver and Intra	<u>ahepatic Bile</u>	<u>Ducts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	NOS			
Male	1.05	0	NC*						
Female	0.49	0	NC*	Female	7.21	7	97		
Total	1.53	0	NC*						
Lung and Bron	<u>chus</u>		<u>A</u>]	ll Sites / Ty	<u>pes</u>				
Male	20.18	12	59	Male	123.74	102	82		
Female	14.28	13	91	Female	121.70	116	95		
Total	34.46	25	73	Total	245.44	218	89		

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

YARMOUTH

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	$\underline{\mathbf{Exp}}$	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>				
Bladder, Urina	<u>ry</u>	<u>lelanoma of</u>	<u>Skin</u>								
Male	31.21	32	103	Male	12.78	16	125				
Female	11.93	18	151	Female	10.11	19	188 #+				
Total	43.14	50	116	Total	22.89	35	153 #+				
Brain and Cen	<u>tral Nervous</u>	System	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>						
Male	7.64	7	92	Male	5.47	8	146				
Female	8.06	12	149	Female	5.21	4	NC*				
Total	15.71	19	121	Total	10.68	12	112				
Breast			Non-Hodgkin's Lymphoma								
Male	1.54	4	NC*	Male	18.91	28	148				
Female	158.72	173	109	Female	19.59	31	158 #+				
Total	160.26	177	110	Total	38.50	59	153 ~+				
Cervix Uteri			Oral Cavity and Pharynx								
				Male	16.62	21	126				
Female	7.98	14	176	Female	8.38	7	83				
				Total	25.01	28	112				
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>							
Male	82.32	94	114								
Female	81.90	57	70 ~-	Female	18.26	26	142				
Total	164.22	151	92								
Esophagus	Esophagus Pancreas										
Male	9.41	8	85	Male	10.62	14	132				
Female	4.06	2	NC*	Female	12.65	19	150				
Total	13.47	10	74	Total	23.27	33	142				
Hodgkin's Disease			Prostate								
Male	2.63	3	NC*	Male	186.53	241	129 ^+				
Female	2.39	1	NC*								
Total	5.02	4	NC*								
Kidney and Renal Pelvis			Stomach								
Male	15.40	22	143	Male	13.49	15	111				
Female	10.04	13	129	Female	8.97	9	100				
Total	25.45	35	138	Total	22.46	24	107				
<u>Larynx</u>	<u>Larynx</u> <u>Testis</u>										
Male	9.64	18	187 #+	Male	2.96	4	NC*				
Female	2.67	1	NC*								
Total	12.31	19	154								
Leukemia	<u>Thyroid</u>										

Male	10.38	16	154	Male	1.81	2	NC*
Female	8.30	10	120	Female	5.25	6	114
Total	18.68	26	139	Total	7.05	8	113
Liver and In		<u>Uteri, Corpus and Uterus, NOS</u>					
Male	4.52	4	NC*				
Female	2.29	0	NC*	Female	30.19	23	76
Total	6.81	4	NC*				
Lung and Bronchus			i	All Sites / Types			
Male	93.50	104	111	Male	575.40	703	122 ^+
Female	66.52	67	101	Female	524.38	558	106
Total	160.03	171	107	Total	1099.77	1261	115 ^+

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

92 of 92

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels